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(4"$"%*4.&&"#$% -$% (4"%*.#*-,+% -($"#9% (4/),34%(4"%.,()6/"3,#.()/:%+"*4.&-$+%C&)A&%.$%!.=@6
-&',*"'% !.=@6/"#".$"% ;!F=!<1% B4-$% 7)$-(-0"% 9""'8.*C% $:$("+% *)&0"/($% .&% "#"+"&(./:% $-3&.#%
"0"&(%-&%.%3#)8.#%*.#*-,+%/"$7)&$"%;!"#$&/-")1(0)/<5%/"$7)&$-8#"%9)/%*)&(/)##-&3%)9%'-0"/$"%(:7"$%








')A&$(/".+% "99"*()/$% -&0)#0"'% -&% )(4"/% $-3&.#-&3% 7.(4A.:5% (4"% *.#*-,+% $-3&.#% -$% .8#"% ()%
+)',#.("%.%0./-"(:%)9%!"#$%10)1(/(90&,-.:01101&(4.(%)7"/.("%)0"/%.%A-'"%("+7)/.#%$7"*(/,+1%
K)&"(4"#"$$5%*"##$%./"%,&.8#"%()%$,$(.-&%.&%"L("&$-0"%.&'%7"/$-$("&(%-&*/".$"%)9%*.#*-,+%
*)&*"&(/.(-)&1% X/)#)&3"'% "#"0.(-)&% )9% *:()$)#-*% !.=@% /"$,#(% -&% +-()*4)&'/-.#% )0"/#).'-&35%
.*(-0.(-)&%)9%7/)(".$"$5%.&'%.*(-0.(-)&%)9%2KU69/.3+"&(-&3%"&I:+"$1%B)%.0)-'%(4"$"%*:()()L-*%
"99"*($5% ",C./:)(-*% *"##$% 4.0"% "0)#0"'% .&% "99-*-"&(% (/.&$7)/(% $:$("+% ()% +.-&(.-&% .'"R,.("%
-&(/.*"##,#./%*)&*"&(/.(-)&%)9%*.#*-,+5%(4"%$)6*.##"'%!.=@%4)+")$(.$-$1%B4-$%+"*4.&-$+%/"$,#($%
9/)+%(4"%*))/'-&.("'%/"+)0.#%)9%*:()$)#-*%!.=@%),(%)9%(4"%7#.$+.%+"+8/.&"%.&'%-&()%-&("/&.#%
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1.1.2 THE CORE OF CALCIUM SIGNALING NETWORK 
B4"% +)$(% $7"*-.#-I"'% +"*4.&-$+% )9% *))/'-&.(-)&% )9% *.#*-,+% $-3&.#-&3% ())#C-(% *.&%
7)$$-8#:% 8"% 9),&'% -&% $C"#"(.#% +,$*#"5% A4"/"% (4"% [6(:7"% \)#(.3"6N7"/.("'% !4.&&"#$% ./"%
'-/"*(#:% *),7#"'% ()% (4"%Y]Y?5% $)% (4.(% (4"% (/.&$+-$$-)&%)9%!"#$%$-3&.#%)**,/$%8:%.&%.##)$("/-*%
0./-.(-)&%)9%7/)("-&%*)&9)/+.(-)&$% ;B$,3)/C.%"(%.?DDQ^%_#"-&%"(%.#1?DDQ<1%!)&$"R,"&(#:5% (4"%
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1.2 THE SERCA PUMP 
1.2.1 THE P-TYPE ATPASE FAMILY 
T&% +.++.#$5% (4/""% *.#*-,+% 7,+7$% 4.0"% 8""&% '"$*/-8"'V% (4"% $./*)7#.$+-*% /"(-*,#,+%
;MPY!U<5%7#.$+.%+"+8/.&"% ;XJ!U<%.&'% (4"%a)#3-%&"(A)/C% ;MX!U<%7,+7$1%U##% (4/""%7,+7$%
8"#)&3% ()% (4"% X6(:7"% UBX.$"$% 9.+-#:5% *4./.*("/-I"'% 8:% (4"% 9)/+.(-)&% )9% .&% "&"/3-I"'%
-&("/+"'-.("5%/"$,#(-&3%9/)+%(4"%.,()674)$74)/:#.(-)&%)9%.%C":%-&0./-.&(%.$7./(.("%/"$-',"%-&%
.%4-34#:%*)&$"/0"'%$"R,"&*"V%M6_BaB[B1%%
U% $"R,"&*"% .#-3&+"&(% )9% 9),/% +.-&% /"7/"$"&(.(-0"$% )9% (4"% 9.+-#:% 9/)+% ,&/"#.("'%
)/3.&-$+$%;_,4#8/.&'(5%=>>W<%$4)A$%*)&$"/0"'%/"3-)&$% -&%*:()7#.$+-*%')+.-&$5%$,*4%.$%(4"%
$-("% A4"/"% (4"% 74)$74)/:#.("'% -&("/+"'-.("% -$% 9)/+"'5% (4"% UBX68-&'-&3% 7)*C"(5% .&'% (4"%
/"3-)&% -&0)#0"'% -&% (4"% '"74)$74)/:#.(-)&% )9% (4"% "&I:+"1% 2"$7-("% (4"% #)A% '"3/""% ;?Eb<% )9%








-)&$V% P?% $(.("% ;4-34% .99-&-(:5% 9.*"'% )&% *:()7#.$+<% .&'% P=% $(.("% ;-)&% #)A% .99-&-(:5% 9.*"'% )&%
"L(/.*"##,#./%$7.*"<%;U#8"/$5%Qc<1%[.("/5%C-&"(-*%'.(.%$4)A"'%(4.(%(4"%"&"/3:%/"R,-/"'%9)/%(4"%
*),7#-&3% )9% 4:'/)#:(-*% .&'% 0"*()/-.#% (/.&$7)/(% 7/)*"$$"$% /"$,#("'% 9/)+% (A)% 74)$74)/:#.("'%
-&("/+"'-.("% $(.("$V% P?!X% ;4-346"&"/3:% -&("/+"'-.("<% .&'% P=6X% ;#)A6"&"/3:% -&("/+"'-.("<%
;d4-((.+5%?DH><1%
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1.2.2 ISOFORMS OF THE SERCA PUMP  
T&%+.++.#$5%.%9.+-#:%)9%(4/""%*)&$"/0"'%3"&"$5%MPY!U%?5%=5%.&'%S5%"&*)'"$%(4/""%+.-&%
MPY!U%7,+7$%.&'%(4"%.#("/&.(-0"%$7#-*-&3%.(%(4"%!NNe6("/+-&.#%)9%(/.&$*/-7($%"&4.&*"$%(4"%
&,+8"/%)9% 7/)("-&% 0./-.&($1%2"0"#)7+"&(.##:% .#("/&.(-0"% $7#-*-&3%)9% MPY!U?%3"&"% /"$,#($% -&%
(A)% (/.&$*/-7(% 0./-.&($% "&*)'-&3% '-99"/"&(% -$)9)/+$V% (4"% MPY!U?.% .&'% MPY!U?8% 7/)("-&$5%
A4-*4%./"%"L7/"$$"'%-&%.',#(%.&'%-&%&")&.(.#%9.$(6(A-(*4%$C"#"(.#%+,$*#"5%/"$7"*(-0"#:1%F)/%(4"%
MPY!U=% 3"&"5% .% (-$$,"6'"7"&'"&(% 7/)*"$$-&3% )9% 7/-+./:% (/.&$*/-7(% -$% /"$7)&$-8#"% 9)/% (4"%
"L7/"$$-)&% )9% (A)% +.-&% -$)9)/+$V% (4"% MPY!U=.% .&'% (4"% MPY!U=8% 7/)("-&$1% B4"% 9-/$(% -$%
"L7/"$$"'% 7/"')+-&.&(#:% -&% *./'-.*% .&'% $#)A6(A-(*4% $C"#"(.#% +,$*#"5% A4-#"% (4"% $"*)&'% -$%
*)&$-'"/"'% (4"% 4),$"C""7-&3% -$)9)/+5% 8"*.,$"% -(% -$% "L7/"$$"'% .(% #)A% #"0"#$% -&%+,$*#"% .&'%
&)&6+,$*#"%*"##$1%U&)(4"/%0./-.&(%)9%(4"%MPY!U%=%3"&"%;MPY!U=*<%4.$%8""&%9),&'%-&%4,+.&%
+)&)*:("$% .&'% 9"(.#% 4"./(1% F-&.##:5% $-L% 7)$$-8#"% 0./-.&($% ;.69<% )9% MPY!US% 3"&"% 4.0"% 8""&%
'"$*/-8"'5% 8,(% )&#:% S% -$)9)/+$% ;.6*<% 4.0"%8""&%'"("*("'% -&% 4,+.&$% .(% 7/)("-&% #"0"#1% B4"$"%
#.(("/% ./"% "L7/"$$"'% -&% .% &,+8"/% )9% &)&6+,$*#"% *"##$1% B4"% "L7/"$$-)&% 7.(("/&% )9% MPY!U%
-$)9)/+$5%A4-*4% *4.&3"$%',/-&3%'"0"#)7+"&(% .&'% (-$$,"%'-99"/"&(-.(-)&5% $,33"$($% (4.(% ".*4%
MPY!U%-$)9)/+%7#.:$%.%$7"*-9-*%9,&*(-)&%-&$-'"%(4"%(-$$,"%-&%A4-*4%-(%-$%"L7/"$$"'1%T&%.''-(-)&5%
$)+"%/"3,#.()/:%+)#"*,#"$%)9%(4"%MPY!U%7,+7%*),#'%"&4.&*"%(4"$"%9,&*(-)&.#%'-99"/"&*"$1%
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-&("/.*(-)&%A.$% -'"&(-9-"'%8:% (4"%*/)$$6#-&C-&3%)9%[:$S% -&% (4"%X[K%')+.-&%()% (4"%[:$SDH%.&'%
[:$W>>%)9% (4"% $"R,"&*"%_22_X\% -&% (4"% *:()$)#-*%K%')+.-&%)9% (4"% MPY!U%7,+7% ;f.+"$5% X15%
?DcD<1%B4-$%$"R,"&*"%-$%*)&$"/0"'%-&%(4"%MPY!U%?%.&'%=%7/)("-&$%.&'%7/)8.8#:%-$%/"$7)&$-8#"%
9)/% (4"%"L*#,$-)&%)9% MPY!U%S% -$)9)/+$% 9/)+% (4"%X[G% -&4-8-()/:% $:$("+1% B4"% $"*)&'% $-("%4.$%
8""&%9),&'%-&%$7"*-9-*%/"$-',"$%)9%(4"%X[K%(/.&$6+"+8/.&"%')+.-&%;=c6E=%/"$-',"$<%(4.(%./"%
/"$7)&$-8#"% 9)/% (4"% 7,+7% -&4-8-(-)&5% /"',*-&3% -($% .77./"&(% *.#*-,+% .99-&-(:1% B4-$% -&4-8-()/:%





&"./#:% S>b% -'"&(-(:%A-(4% (4.(% )9% 74)$74)#.+8.&% ;X[K<5% *)&9-/+-&3% -($% /)#"% .$% .&% -&4-8-()/:%
$-("1%Y"*"&(%)8$"/0.(-)&$%4.0"%'"+)&$(/.("'%(4.(%M[K%-$%*)6"L7/"$$"'%A-(4%MPY!U=.%-&%+)'"#%
*"##$% .&'% (4-$% -$% /"#.("'% ()% .% $,7"/6-&4-8-(-)&% )9% (4"% 7,+71% T&% .''-(-)&5% KJY% $(,'-"$% 4.0"%
$,33"$("'%(4.(%(4"%(A)%/"3,#.()/:%7/)("-&$%8-&'%()%MPY!U%-&%.%$-+-#./%+.&&"/1%e)A"0"/5%(4"%
74:$-)#)3-*.#%$-3&-9-*.&*"%)9%(4"%MPY!U%7,+7%/"3,#.(-)&%8:%M[K%/"+.-&$%()%8"%"#,*-'.("'1%
1.2.4 REGULATION OF SERCA2A ACTIVITY 
U$%+"&(-)&"'5%X[K%-$%(4"%+.g)/%/"3,#.()/%)9%MPY!U=.%.*(-0-(:%.&'%$)%9./%-$%(4"%)&#:%)&"%
(4.(% A.$% 7/)0"&% ()% 8"% -&0)#0"'% -&% *./'-.*% '"0"#)7+"&(5% -&*#,'-&3% 4"./(% 9.-#,/"1% B4"% X[K6
+"'-.("'% -&4-8-(-)&% )9% MPY!U=.% -$% 9-&"#:% /"3,#.("'% 8:% 74)$74)/:#.(-)&% )9% (4/""% '-$(-&*(%
74)$74)/:#.(-)&% $-("$% ;M"/% ?>5% M"/% ?Q5% B4/% ?H<% -&% (4"% /"3,#.()/:% ')+.-&% )9% X[K5%A4-*4% ./"%
*)&(/)##"'% 8:% (4/""% '-99"/"&(% 7/)("-&% C-&.$"$% ;7/)("-&% C-&.$"% !% ;X_!<5% *UJX6'"7"&'"&(%
7/)("-&% C-&.$"% ;X_U<% .&'% !.=@6*.#+)',#-&% 7/)("-&% C-&.$"% ;!.J_TT<1% X4)$74)/:#.(-)&% )9% ".*4%
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/"$-',"% -$% /"#.("'% ()% .&% -&*/".$"% -&% MPY!U=.% .*(-0-(:% .$% .% /"$,#(% )9% (4"% .$$)*-.(-)&% )9% X[G%
+)&)+"/$% -&()% 7"&(.+"/1%N&% (4"% )(4"/% "&'5% '"74)$74)/:#.(-)&% 0-.% 7/)("-&% 74)$74.(.$"% T%
;XXT<% /"$()/"$% (4"% -&4-8-()/:% "99"*($% )9% X[K% )&% MPY!U=.1% B4-$% /"$,#($% -&% .% '"*/".$"% -&% !.=@%
.99-&-(:%.$%.%*)&$"R,"&*"%)9%MPY!U=.ZX[K%-&("/.*(-)&5%A4-*4%$(.8-#-I"$%(4"%"&I:+"%-&%(4"%P=%
*)&9)/+.(-)&5% *.,$-&3% (4"% -&4-8-(-)&% .&'% (4"% .33/"3.(-)&% )9% (4"% 7,+71% B4"% .*(-0-(:% )9% (4"%
MPY!U%7,+7%-$%+)',#.("'%8:%h%.'/"&"/3-*%$-3&.##-&3%7.(4A.:%(4/),34%(4"%74)$74)/:#.(-)&%)9%
-&4-8-()/%T%0-.%7/)("-&%C-&.$"%U1%U'/"&.#-&"%.&'%)(4"/%h6.3)&-$($%-&-(-.("%.&%-+7)/(.&(%$-3&.#6
(/.&$',*(-)&% 7.(4A.:5% A4"/"% (4"% -&*/".$"% -&% (4"% *UJX% *)&*"&(/.(-)&% .*(-0.("$% *UJX6
'"7"&'"&(%7/)("-&%C-&.$"%;X_U<5%A4-*4%(4"&%74)$74)/:#.("$%.&'%.#("/$%(4"%9,&*(-)&%)9%.%9"A%
*./'-.*% 7/)("-&$1% T&% 9.*(5% (4"% $"/-&"?Q% $-("% .77"./$% ()% 8"% (4"%+)$(% -+7)/(.&(%+"'-.()/% ()%
"&4.&*"%*./'-.*%*)&(/.*(-#-(:%.&'%4.$%8""&%$,33"$("'%()%8"%(4"%+.-&%/"3,#.()/%)9%(4"%.*(-0-(:%
)9%74)$74)#.+8.&1%
1.3 STRUCTURAL PROPERTIES OF SERCA PUMP. A DETAILED OVERVIEW 
1.3.1 E1 VERSUS E2: THE FIRST STEPS INSIDE THE MOLECULAR UNDERSTANDING OF REACTION CYCLE 
M-&*"% (4"% 9-/$(% 7/"'-*(-)&% )9% (4"% $(/,*(,/"% )9% (4"% MY% !.=@6UBX.$"% ;MPY!U<% 4.$% 8""&%
7/)7)$"'%+)/"%(4.&%=>%:"./$5%.%4,3"%&,+8"/%)9%8-)*4"+-*.#%.&'%+,(.(-)&.#%.&.#:$"$%4.0"%
8""&% .**,+,#.("% ()% *#./-9:% (4"% +)#"*,#./% .$7"*($% )9% (4"% /".*(-)&% *:*#"% .&'% (4"% /"3-)&%
-&0)#0"'% -&% (4"%"&I:+.(-*% *.(.#:$-$1% F/)+%(4-$% $*"&./-)5% (4"%MPY!U%"+"/3"'% #-C"%.&% -&("3/.#%
+"+8/.&"% 7/)("-&% )9% .8),(% ??>% _2.5% *)&$-$(-&3% )9% (4/""% *:()7#.$+-*% ')+.-&$% g)-&"'% ()% .%
3/),7%)9%?>%(/.&$+"+8/.&"%;BJ<%4"#-*"$%;J?6J?><%8:%.%$4)/(%1/"4?%$"3+"&(%;J.*["&&.&%"(%
.#15%?DcE^%G/.&'#%"(%.#15%?DcQ^%B.:#)/%.&'%a/""&5%?DcD<1%B4"%*/-(-*.#%/"$-',"$%9)/%!.=@%8-&'-&3%
.&'% (4)$"% 9)/% UBX% 4:'/)#:$-$5% -'"&(-9-"'% 8:%+,(.3"&"$-$% $(,'-"$5% 4.0"% 8""&% #)*.("'% -&% (4"%
+-''#"% )9% (4"% (/.&$+"+8/.&"% 4"#-*"$% ;!#./C"% "(% .#15% ?DcD^% !4"&% "(% .#15% ?DDQ<5% .&'% -&% (4"%
*:()7#.$+-*%')+.-&%8"(A""&%(4"%JW%.&'%JE%4"#-*"$% ;J./,:.+.%"(%.#15%?DcD^%!#./C"%"(%.#15%
?DD>.^%\-#$"&%"(%.#15%?DD?<5%/"$7"*(-0"#:1%U%&,+8"/%)9%8-)*4"+-*.#%'.(.%4.0"%8""&%*)##"*("'%()%










*/:$(.#% $(/,*(,/"% )9% !.=@68),&'% MPY!U% .(% =1Q% i% /"$)#,(-)&5% $)#0"'% 8:% B):)$4-+.j$% 3/),7%
;B):)$4-+.5% !1% "(% .#5% =>>><1% T(% 4.$% /"7/"$"&("'% .% +-#"$()&"% -&% (4"% ,&'"/$(.&'-&3% )9% (4"%
+)#"*,#./%+.*4-&"%/"$7)&$-8#"%9)/%(4"%*.#*-,+%7,+7-&3%.&'%-(%4.$%7,(%(4"%8.$"+"&(%9)/%(4"%
8,-#'-&3% )9% .##% (4"% 9)##)A-&3% C&)A#"'3"% .8),(% (4"% X6(:7"% UBX.$"% 9.+-#:1% MPY!U% */:$(.#%
$(/,*(,/"%4.$%*)&9-/+"'%(4"%3"&"/.#%./*4-("*(,/"%)9%(4"%7,+75%*)&$-$(-&3%-&%(4/""%*:()7#.$+-*%
')+.-&$5% K% ;&,*#")(-'"% 8-&'-&3<5% X% ;74)$74)/:#.(-)&% /"$-',"<5% .&'% U% ;.*(,.()/<5% .&'% ?>%
(/.&$+"+8/.&"%4"#-*"$%;J?6J?><%$,//),&'-&3%(A)%*.#*-,+68-&'-&3%$-("1%%
T&% (4"% */:$(.##)3/.74-*% $(/,*(,/"% )9% !"378% $(.("% (4/""% *:()7#.$+-*% ')+.-&$% ./"% A"##%
$"7./.("'%()%9)/+%.&%.,0)&;0"*,(0:05% -&%A4-*4%(4"%*"&(/.#%7./(%)9%(4"%*:()7#.$+-*%/"3-)&%-$%
)**,7-"'%8:%')+.-&%X5%*)&(.-&-&3%(4"%*)&$"/0"'%74)$74)/:#.(-)&%/"$-',"%;U$7SE?<1%U/),&'%
(4-$% $-("5% (4"% /"$-',"$% */-(-*.#% 9)/% UBX% 4:'/)#:$-$% -$% *#,$("/"'5% 9)/+-&3% .% 4-34#:% &"3.(-0"#:%
*4./3"'% $,/9.*"5% .**"$$-8#"% ()% (4"% $)#0"&(1% B4"% ')+.-&% K% -$% (4"% #./3"$(% )9% (4"% (4/""%
*:()7#.$+-*%')+.-&$5%.&'%*)&(.-&$%(4"%&,*#")(-'"68-&'-&3%$-("%;X4"%WcH<1%2)+.-&%U5%(4"%$)6
*.##"'%":/N"/.-&*.3"()5% -$% (4"% $+.##"$(%)9% (4"% (4/""%.&'% -$% *)&&"*("'% ()% (4"%J?6JS% (/.&$6
+"+8/.&"%4"#-*"$%8:%#)&3%9#"L-8#"%#))7$1%T&%.''-(-)&5%-(%*)&(.-&$%.&)(4"/%$-3&.(,/"%$"R,"&*"%
)9% X6(:7"% UBX6.$"% 9.+-#:5% (4"% BaPM%+)(-91% B4"% (A)% !.=@% 8-&'-&3% $-("$% ;T% .&'% TT<% ./"% -&'""'%
"+8"''"'%$-'"%8:%$-'"%-&%(4"%(/.&$6+"+8/.&"%')+.-&1%M-("%T%-$%#)*.("'%-&%(4"%$7.*"%8"(A""&%
4"#-*"$%JE% .&'%JQ5% A-(4% *)&(/-8,(-)&% 9/)+%Jc% .(% .% /.(4"/% '-$(.#% 7)$-(-)&^% (4"% $-'"% *4.-&%
)L:3"&%.()+$%)9%U$&HQc5%a#,HH?%;JE<5%B4/HDD5%U$7c>>%;JQ<%.&'%a#,D>c%;Jc<%*)&(/-8,("%()%
(4-$% $-("5% -&%.3/""+"&(%A-(4%+,(.(-)&.#% $(,'-"$1%M-("% TT% -$% 9)/+"'%.#+)$(%)&%4"#-L%JW%8:% (4"%
+.-&6*4.-&% *./8)&:#% )L:3"&% .()+$% )9% \.#S>W5% U#.S>E% .&'% T#"S>H% ;JW<% .&'% (4"% $-'"6*4.-&%
)L:3"&%.()+$%)9%U$&HDQ5%U$7c>>%;JQ<%.&'%a#,S>D%;JW<%;c<1%B4"%JW%.&'%JE%4"#-*"$%./"%(4"%
#./3"$(% )9% (/.&$6+"+8/.&"% ')+.-&% .&'% (4"-/% *:()7#.$+-*%+)-"(:% ./"% '-/"*(#:% *)&&"*("'% ()%
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(4"%*.(.#:(-*% *)/"%)9% (4"%X6')+.-&1% T&% 9.*(5% (4"%JE%4"#-L% -$% *)&$-'"/"'% (4"%8.*C8)&"%)9% (4"%
MPY!U%$(/,*(,/"1%
M,/7/-$-&3#:5% (4"% #)&3% '-$(.&*"% 8"(A""&% (4"% &,*#")(-'"68-&'-&3% .&'% 74)$74)/:#.(-)&%
$-("$% ;=E%i<5% .&'% (4.(%8"(A""&% (4"%74)$74)/:#.(-)&%.&'% -)&68-&'-&3% $-("$% -&% (4"%+"+8/.&"%
;.8),(% WE% i<% )7"&"'% ,&$)#0"'% R,"$(-)&$% .8),(% (4"%+)#"*,#./%+"*4.&-$+% (4.(% *),7#"% (4"%
74)$74)/:#.(-)&%7/)*"$$%()%(4"%*.#*-,+%/"#".$"1%e)A%')"$%(4"%UBX%8-&'-&3%)&%(4"%K%')+.-&%
(/.&$9"/%(4"%74)$74.("%()%(4"%U$7SE?%#)*.("'%-&%.&)(4"/%')+.-&k%U&'%4)A%*.&%(4-$%/".*(-)&%
8"% .$$)*-.("'% A-(4% (4"% *.#*-,+% /"#".$"% -&% (4"% #,+"&% )9% $./*)7#.$+-*% /"(-*,#,+k% U$% (4"% X%
')+.-&%7/"$"&(%$(/,*(,/.#%$-+-#./-(:%A-(4%(4"%*.(.#:(-*%*)/"%)9%4.#).*-'%'"4.#)3"&.$"5% -(%A.$%
$,33"$("'% (4.(% .% 7)$$-8#"% /".//.&3"+"&(% )9% (4"% )0"/.##% $(/,*(,/"5% -&% (4"% 7/"$"&*"% )9% !.=@5%
*),#'%$4.7"%.&%KZX%')+.-&%-&("/9.*"%A4"/"%(4"%74)$74)/:#.(-)&%7/)*"$$%*.&%(.C"%7#.*"1%U$%.%
*)&$"R,"&*"%)9% (4-$% -&("/.*(-)&5% (4"%U%')+.-&% *),#'% (/.&$+-(% (4"%+"*4.&-*.#% $-3&.#% ()% (4"%
(/.&$6+"+8/.&"%')+.-&5%(4.(%-&%(,/&%/"#".$"$%(4"%!.=@%8),&'%-&%(4"%MY%#,+"&1%%
M(/,*(,/.#% "0-'"&*"$5% /"$,#(-&3% 9/)+% (4"% *)+7./-$)&% )9% (4-$% $(/,*(,/"% A-(4% .% #)A6
/"$)#,(-)&% "#"*(/)&% '"&$-(:% +.7% )9% (4"% $.+"% "&I:+"% -&% (4"% 0.&.'.("6-&4-8-("'% P=OX%
*)&9)/+.(-)&% ;l4.&35% X15% ?DDc<5% 4.0"% $,33"$("'% (4.(% /-3-'68)':% /".//.&3"+"&($% )9%
*:()7#.$+-*%')+.-&$%(.C"%7#.*"%',/-&3%.*(-0"%(/.&$7)/(5%-&%.3/""+"&(%A-(4%8-)*4"+-*.#%'.(.1%
B4-$%-&("/7/"(.(-)&%A.$%9-&.##:%*)&9-/+"'%8:%(4"%*/:$(.#%$(/,*(,/"%)9%!.=@%9/""%MY%!.=@6UBX.$"%
-&% (4"% (4.7$-3./3-&6$(.8-#-I"'% P=% $(.("5% $)#0"'% .(% S1?i% /"$)#,(-)&% ;B):)$4-+.5% =>>=<1% d-(4%




1.3.2 E1-P PHOSPHO-INTERMEDIATE STRUCTURES AS A RESPONSE TO ATP-BINDING SITE CONTROVERSY 
G-)*4"+-*.#%$(,'-"$%4.'%A"##%"$(.8#-$4"'%(4.(%(4"%*.(.#:(-*%*:*#"%)9%MPY!U%7,+7%(.C"$%









(/.&$+-(("'% ()% (4"% (/.&$6+"+8/.&"% ')+.-&% -&% )/'"/% ()% /"#".$"% (4"% *.#*-,+% -&()% (4"% MY%
#,+"&5% .$% /"$7)&$"% ()% 74)$74)/:#% (/.&$9"/1% N&% (4"% )(4"/% 4.&'5% (4":% 4.0"% .#$)% $7./C"'% .%
'"8.("% .8),(% (4"% $(/,*(,/.#% 8.$-$% )9% (4"% UBX% 8-&'-&3% 7)*C"(% .&'% 4.0"% #"9(% ,&$)#0"'% (4"%
+)#"*,#./%,&'"/$(.&'-&3%)9%+"*4.&-$+$%(4.(%*),7#"%(4"%74)$74)/:#%(/.&$9"/%/".*(-)&%()%(4"%
!.=@%)**#,$-)&%-&%(4"%P?6X%$(.("1%
B4"% 9-/$(% $(/,*(,/.#%"0-'"&*"% (4.(% (/-"'% ()%8/-'3"% (4"$"%3.7$% /"$,#("'% 9/)+%(A)%*/:$(.#%
$(/,*(,/"$%)9%MPY!U5%$)#0"'%8:%K-$$"&j$%3/),7%.(%=1Q%.&'%=1D%i5%/"$7"*(-0"#:V%(4"%!.=@%8),&'%
MPY!U% ;!"#7839:;;!;<% -&% *)+7#"L% A-(4% .% &)&64:'/)#:$.8#"% UBX% .&.#)3,"5% UJXX!X%
m.'"&)$-&"% ;"6#% +"(4:#"&"<6(/-74)$74.("n5% .&'% (4.(% ;!"#78396;<95=>
3<% -&% *)+7#"L% A-(4%
.'"&)$-&"%'-74)$74.("%7#,$%.#,+-&-,+%9#,)/-'"5%.&%-&)/3.&-*%74)$74.("%.&.#)3,"%;M)/"&$"&5%













4"#-L% ()A./'$% (4"% *:()7#.$+5% .&'% (4"% 8"&'-&3% )9% (4"% J?% -&% .% 7./.##"#% 7)$-(-)&% ()% (4"%




6% .&.#)3,"$% .(% (4"% *.(.#:(-*% *)/"% "&.8#"'% ()% -'"&(-9:% */-(-*.#% /"$-',"$% 9)/%
&,*#")(-'"% 8-&'-&35% $,33"$(-&3% .% 7)$$-8#"% *4"+-*.#% /".*(-)&%+"*4.&-$+% 9)/% (4"% 74)$74)/:#%
(/.&$9"/5% -&%.3/""+"&(%A-(4%+,(.(-)&.#%'.(.1%U$%(4"%&,*#")(-'"68-&'-&3%7)*C"(% -$%.$$"+8#"'%
.(% (4"% -&("/9.*"%8"(A""&% (4"%K%.&'%X%')+.-&$5%.$%.% /"$7)&$"% ()% (4"%$% $(.*C-&3% -&("/.*(-)&%








+)#"*,#"% 8/-'3"$% 8"(A""&% (4"% "674)$74.("% .&'% (4"% $-'"% *4.-&% )9% U$7SE?5% +)'-9:-&3% (4"%
-&("/.*(-)&$%)9%(4"%.+-&)%.*-'%/"$-',"$%-&0)#0"'%-&%74)$74)/:#%(/.&$9"/5%8:%(4"%*))/'-&.(-)&%
)9% (A)% J3=@% -)&$1% M,/7/-$-&3#:5% 8)&'-&3% '-$(.&*"$% ;!=% i<% )9% (4"% .()+$% (4.(% */)$$6#-&C%
.#,+-&-,+%A-(4%"674)$74.("%.&'%U$7SE?%)L:3"&%.()+$%./"%-&%.3/""+"&(%A-(4%(4"%4:7)(4"$-$%
)9% .% 7)$$-8#"% &,*#")74-#-*% /".*(-)&% +"*4.&-$+% ;MK=<% (4.(% A.$% 9-&.##:% $,33"$("'% ()% 8"%
/"$7)&$-8#"%9)/%(4"%.$7./(:#674)$74)/:#.("'%-&("/+"'-.("%9)/+.(-)&1%
T&%.''-(-)&5%B):)$4-+.j$%3/),7%7,8#-$4"'%(4"%*/:$(.#%$(/,*(,/"%)9%!.=@%8),&'%MPY!U%-&%.%
*)+7#"L%A-(4% UJXX!X% ;78•9:;;!;<% .(% =1D% i% -&% (4"% $.+"% :"./% ;B):)$4-+.5% =>>W<1% T&% (4-$%
7.7"/5% (4"% $(/,*(,/"% -$% 0"/:% $-+-#./% ()% (4.(% 7/"0-),$#:% '"$*/-8"'5% 8,(% (4"% .,(4)/$% ,$"'%
"0-'"&*"$% '"/-0"'% 9/)+% $(/,*(,/.#% $,7"/-+7)$-(-)&% ()% "+74.$-I"% (4"% /)#"% )9% UBX% .$% (4"%
7/-+./:%+)'-9-"/% )9% (4"% 7/)("-&% *)&9)/+.(-)&5% .&'% (4)$"% )9% a#,S>D5% .$% (4"% 3.(-&3% /"$-',"%
/"$7)&$-8#"% 9)/% *:()7#.$+-*% )**#,$-)&% )9% (/.&$+"+8/.&"% !.=@% 8-&'-&36$-("1% G:% (4"%
$,7"/-+7)$-(-)&% )9% (4"% P?p=!.=@% .&'% P?pUJXX!X% *)&*#,$-)&$% .8),(% (4"% 7/)("-&%
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& (.)1& "-0& 1;.@)& "1& ,N-,40& 1,;0-01O&@;0-0"1& ()& B#WTcA& -0*&
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& -0,-010)/& /;0& *(-0:/(.)& .2& -0"--")+030)/1& .2&
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&
K(+M& dM& !..-*()"/(.)& .2& /;0& /@.& /5,01& .2& )N:40./(*0& ")"4.+N01& '5& I+
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1.3.3 E2-P PHOSPHO-INTERMEDIATE STRUCTURES AND THE CATALYTIC CYCLE IS COMPLETED  
M(/,*(,/.#% "0-'"&*"% .8),(% #)A% "&"/3:% -&("/+"'-.("$% -&0)#0"'% -&% !.=@% /"#".$"% .&'%
*),&("/6(/.&$7)/(% .//-0"'% -++"'-.("#:% .9("/1% T&% =>>W5% B):)$4-+.% 7/"$"&("'% (4"% */:$(.#%
$(/,*(,/"% )9% !.=@69/""% /.88-(% MPY!U% ;7#3:?=>
#3<% -&% .% *)+7#"L% A-(4% +.3&"$-,+% 9#,)/-'"5% .%
$(.8#"%74)$74.("%.&.#)3,"5%.&'%(.7$-3./3-&%;Ba<5%.&%-&4-8-()/5%.(%=1S%i%/"$)#,(-)&%;B):)$4-+.5%
=>>W<1%B4-$%$(/,*(,/"%*.&%8"%*)&$-'"/"'%()%/"7/"$"&(%(4"%P=6X%$(.("%)9%(4"%"&I:+"%.9("/%(4"%
4:'/)#:$-$% )9% .$7./(:#674)$74.("5% 8,(% 8"9)/"% (4"% /"#".$"% )9% (4"% -&)/3.&-*% 74)$74.("1%d-(4%
/"$7"*(% ()% (4"% !.=@68),&'% P?6U#FWpU2X% $(/,*(,/"5% $)#0"'% 8:% (4"% $.+"% 3/),7% -&% (4"% $.+"%
:"./$5%(4-$%+)#"*,#./%+)'"#%$4)A$%.%(-34(%.$$)*-.(-)&%8"(A""&%(4"%U%.&'%X%')+.-&$%.$%/"$,#(%
)9% (4"% U% ')+.-&% /)(.(-)&% 8:% ??>o% ./),&'% .&% .L-$% 7"/7"&'-*,#./% ()% (4"% +"+8/.&"1%
!)&$"R,"&(#:5% /".//.&3"+"&($% )9% $-L% ;J?6JQ<% (/.&$+"+8/.&"% 4"#-*"$% '"$(/):% (4"% 4-34%
.99-&-(:% !.=@% 8-&'-&3% $-("% .&'% )7"&% (4"% #,+-&.#% 3.("5% 9)/+"'% 8:% J?% .&'% J=% 4"#-*"$1% B4"%
'/.$(-*%*4.&3"%A-(4%/"$7"*(%()%(4"%"./#-"/%$(/,*(,/"$%-$%/"#.("'%()%(4"%/"#".$"%)9%U2X%9/)+%(4"%
&,*#")(-'"68-&'-&3% 7)*C"(1% B4-$% '-$$)*-.(-)&% +)'-9-"$% (4"% K% .&'% X% ')+.-&$% -&("/.*(-)&$5%
*/".(-&3%.% $7.*"% 9)/% (4"%$,8$"R,"&(% -&$"/(-)&%)9% (4"%U%')+.-&%8:% (4"%BaPM%$-3&.(,/"% #))71%




)9% (A)% *))/'-&.("'% "99"*($V% (4"% '"$(/,*(-)&% )9% (4"% 4-34% .99-&-(:% *)&9)/+.(-)&% )9% (4"% !.=@%
8-&'-&3%$-("5%.$%.%*)&$"R,"&*"%)9%(4"%8"&'-&3%)9%JE%()A./'$%J?%.&'%)9%)&"%(,/&%)9%JW%%6




$(/,*(,/"% -&% )/'"/% ()% *#./-9:% (4"% +)#"*,#./% /".//.&3"+"&($% (4.(% (.C"% 7#.*"% ',/-&3% (4"% P=6
X&P=% (/.&$-(-)&1% B4"%+)$(% -+7)/(.&(% "0-'"&*"%A.$% 9),&'% -&% (4"% (/.&$6+"+8/.&"%')+.-&1%






/"$7)&$"% ()% .% 9,/(4"/% (-#(-&3% )9% (4"% U% ')+.-&% 8:% S>o% *.,$"'% 8:% (4"% /"#".$"% )9% J3=@1% B4"%
#,+"&.#%4.#9%)9% (4"%JW%4"#-L% ;JW[<% -$% (,/&"'%8:%q=>o% -&%P=;Ba<%.&'% $4)A$%.% *4.&3"% -&% (4"%
)/-"&(.(-)&%)9% (4"% #))7%*)&(.-&-&3%a#,S>D% (4.(% *#)$"$% (4"% #,+-&.#% 3.("1% F-&.##:5% .% $*4"+.(-*%




W'4N0A& /.& /;0& :"-'.H5& /0-3()N1M& & F)& './;& /;0& 1/-N:/N-01O& /;",1(+"-+()& (1& -0,-010)/0*& "1& ,N-,40& //-(")+40M& DN-,40&
"--.@1&()&B#%I+KR#%&-0,-010)/1&/;0&*(-0:/(.)&.2&J&*.3"()&-0"--")+030)/&*N-()+&/;0&/-")1(/(.)&2-.3&B#%D&/.&B#&
1/"/01M&J*",/0*&2-.3&T.5.1;(3"O&!M&0/&"4O&#QQRM&
1.3.4 INSIGHT INTO THE TRANSPORT MECHANISM COUPLED TO ATP HYDROLYSIS  
B)%,&'"/$(.&'%(4"%'"74)$74)/:#.(-)&%+"*4.&-$+%(4.(%*)&*#,'"$%(4"%UBX%4:'/)#:$-$5%-&%
=>>W% K-$$"&% "(% .#1% '"("/+-&"'% (4"% */:$(.#% $(/,*(,/"% )9% (4"% 7/)()&68),&'% P=% /.88-(% MPY!U5%
$(.8-#-I"'%8:%.#,+-&,+%9#,)/-'"%;U#FW
6%<%.&'%(.7$-3./3-&%;Ba<5%.(%Si%/"$)#,(-)&%;N#"$"&5%!1%"(%.#5%
=>>W<% d-(4% /"$7"*(% ()% (4"% )(4"/% $(.8#"% 74)$74.("% .&.#)3,"% ;J3FW
=6<5% (4"% *))/'-&.(-)&% )9%
/"$-',"$%-&0)#0"'%-&%(4"%74)$74)/:#.(-)&%7/)*"$$%A.$%R,-("%'-99"/"&(5%'"+)&$(/.(-&3%(4.(%(4"%
7#395=>





@5% (4"% 74)$74)/:#.("'% /"$-',"% ;U$7SE?<% -&% (4"% 7#395=>
@%
$(/,*(,/"% -&("/.*($%A-(4%(4"%BaPM%+)(-9%)9% (4"%U%')+.-&5%.$%.%*)&$"R,"&*"%)9%.&%U%')+.-&%
/)(.(-)&% 8:% ??>o% ',"% ()% (4"% U2X% /"#".$"1% B4"% 74)$74.("% .&.#)3,"% *))/'-&.(-)&% A-(4% (4"%
*./8)L:#%3/),7%)9%a#,?cS%.&'%(4"%+.-&%*4.-&%*./8)&:#%)9%B4/?c?%9("%.%A.("/%+)#"*,#"% -$% -&%
.3/""+"&(% A-(4% (4"% .$$)*-.(-0"% MK=% /".*(-)&% 7/)7)$"'% 9)/% '"74)$74)/:#.(-)&5% *)&9-/+-&3%
a#,?cS%.$%.% *.(.#:(-*%8.$"5%.8#"% ()%"L(/.*(%.%7/)()&% 9/)+%.%A.("/%+)#"*,#"1% T($% $,8$"R,"&(%
.((.*C% ()% (4"% 74)$74.("% 3/),7% -$% -&% .3/""+"&(%A-(4%+,(.(-)&.#% '.(.1% U% $-+-#./% .$$)*-.(-0"%
/".*(-)&% +"*4.&-$+% 4.$% 8""&% 7/)7)$"'% .#$)% 9)/% (4"% 74)$74)/:#% (/.&$9"/% 9/)+% UBX% .&'%
/"7/"$"&($%(4"%C":%"#"+"&(%9)/%"L7#.-&-&3%(4"%*),7#-&3%+"*4.&-$+$%)9%MPY!U1%T(%/"$(/-*($%(4"%
9-"#'% )9% 7)$$-8#"% *)&9)/+.(-)&.#% $(.("$% -&% A4-*4% (4"% 74)$74)Z'"74)$74)/:#.(-)&% /".*(-)&$%
*),#'%)**,/1%%




.*(,.()/% )9% (4"% (/.&$#)*.(-)&Z'"74)$74)/:#.(-)&% *),7#"'%+"*4.&-$+1%Y".//.&3"+"&($% )9% .%
9-0"%4"#-*"$%*#,$("/5%9)/+"'%8:%(4"%/"$-',"$%)9%(4"%!6("/+-&.#%7./(%)9%(4"%X6')+.-&%.&'%8:%U6
J=%.&'%U6JS%*4.-&$%.&'%(4"%*)//"$7)&'-&3%$"3+"&($%)9%(4"%U6')+.-&5%()3"(4"/%A-(4%(4"%_@%
-)&% 8),&'% .(% a#,HS=% ;["0:5% 21% "(% .#5% ?DD><% A"/"% 9),&'% */-(-*.#% 9)/% *),7#-&3% (4"% !.=@Ze@%
"L*4.&3"%.&'%(4"%'"74)$74)/:#.(-)&%"0"&($1%P0-'"&*"$%.8),(%)**#,'"'%7/)()&$%*),#'%&)(%8"%
)8$"/0"'%'-/"*(#:5%8"*.,$"%(4"%.()+-*%-&("/.*(-)&$%A-(4%(4"%(.7$-3./3-&%-&4-8-()/%7/)',*"'%.%
$(/,*(,/.#% ./(-9.*(5% 8,(% (4"%A"/"% '"',*"'% 9/)+% $"0"/.#% 8-)*4"+-*.#% '.(.1% F)/% -&$(.&*"5% (4"%





N&% (4"% 8.$-$% )9% $(/,*(,/.#% .&.#:$-$% .&'% 8-)*4"+-*.#% '.(.5% (4"% .,(4)/$% 7/)7)$"'% .%






.&'% '"74)$74)/:#.(-)&5% /"$7"*(-0"#:5% 9)*,$"'% )&% (4"% (/.&$-"&(% 9)/+.(-)&% )9% )**#,'"'% -)&6
8-&'-&3%$-("$5%*)&(/)##"'%8:%(4"%7-$()&6#-C"%+)0"+"&($%)9%(4"%U%')+.-&1%BA)%3.("$%9.*"'%)&%
*:()7#.$+%.&'%$./*)7#.$+-*%#,+"&5%/"$7"*(-0"#:5%A"/"%-'"&(-9-"'1%M(/,*(,/.##:5%(4"%9)/+.(-)&%
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1.4 THE HUMAN SERCA PUMPS GENE MUTATIONS 
BA)% 4,+.&% '-$".$"$% .$$)*-.("'% A-(4% (4"% MPY!U% 7,+7% 3"&"% '"9"*($% 4.0"% 8""&%
'"$*/-8"'% ,&(-#% &)A5% G/)':j$% .&'%2./-"/j$% '-$".$"1% B4"% 9)/+"/% -$% .% /./"% /"*"$$-0"%+,$*,#./%
*)&'-(-)&% *4./.*("/-I"'% 8:% .&% "L"/*-$"6-&',*"'% -+7.-/+"&(% )9%+,$*#"% /"#.L.(-)&% ;G/)':% TU5%
?DQD<1% B4"% ,&'"/#:-&3% *.,$"% 9)/%+,$*#"% *)&(/.*(,/"% 4.$% 8""&% 9),&'% ()% 8"% .$$)*-.("'% ()% .%
MPY!U% /"',*"'% .*(-0-(:5% /"$,#(-&3% 9/)+% .% '"9"*(% )9% (4"% 3"&"% *)'-&3% 9)/% MPY!U?.% -$)9)/+%
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!"#$@M:V)$@.A,3I$/.0$"61+3$%&'()*+$NE1+I#3#-$[12_?$\#0=,3?$[#01+3>R$B+-$+14=,/,#A$
2>$T('$+3A$@=.3#A$,35.$4`#:T]G$4=+-1,A$N9,3A=>$40.C,A#A$2>$J+0@$=#$J+,0#?$Na3,C#0-,5b$T+0,-M
%6A?$ PMc7dG8$Z0-+>?$ E3-5,565$ A#$ \,.=.I,#$ #5$ !#@"3.=.I,#-$ A#$ %+@=+>$ N,\,!#@M%R$ [,/M-60M`C#55#?$
+3A$a')$(V'%?$P0+3@#R$ ,3$5"#$-+1#$@.A,3I$/0+1#$./$5"0.12,3$@=#+C+I#$-,5#$+3A$\):$N2,.5,3$
+@@#45.0$A.1+,3R$-#K6#3@#-$2>$5"#$I+4M0#4+,0$@=.3,3I$1#5".A$N(",3.?$);$#5$+=?$*G7GR;$$
!"#$ /.0B+0A$ N8eM+5+$ @55$ @5+$ 5+I$ +@+$ @I@$ +++$ @+@$ +++$ 5+@$ +@+$ @+@$ 5++$ +55$ +@@$ I++$ 55@$





A,0#@5#A$165+I#3#-,-$ -50+5#I>$ N%50+5+I#3#R$ 5.$#=,1,3+5#$+$ 5"0.12,3$@=#+C+I#$-,5#$B,5",3$ 5"#$
40.5#,3$-#K6#3@#;$
(.14#5#35$%;$@#0#C,-,+#$@#==-$ N-50+,3$gQGQ;72$[+=dh*$N+?$ =#6*?$",-Q?$ 5047i$!'T7M[)U7GM
[)Ud?$ 60+Q?$ +A#*h7?$ @+30?$ @,0<R$ B#0#$ 50+3-/.01#A$ B,5"$ 5"#$ 4`#:T]G$ C#@5.0$ @.35+,3,3I$









!"#$% &$% '()*+",% -./012% 3*.,% 412% 5.0.21(1#13*% .672.**"18% 14% 59:;<=>);?@ABCD=E% "8% 9$% /.2.-"*").$% F2"% D)/0$G%








P5.% )+"81% )/",*% *.R3.8/.% 14% 9:;<=>);?@AB%)40.2% /(18"8#%W)*%)("#8.,%W"05% "0*%W"(0C0K7.% /1380.27)20% HK% 3*"8#%




3.2.2 PROTEIN EXPRESSION 
)$ 5.5+=$ ./$ 7G$1U$ ./$1,3,1+=$1#A,61$ NG;7H$BSC$ \+@5.$ (+-+1,3.$ +@,A-$ N\:$:,+I3.-5,@$
%>-5#1-?$Vj?$a;%;);R?$G;FH$BSC$>#+-5$3,50.I#3$2+-#?$*H$BSC$I=6@.-#?$*G$kIS1U$+A#3,3#R$B#0#$
,3.@6=+5#A$B,5"$5"#$-#=#@5#A$@=.3#$+3A$,3@62+5#A$+5$*Y$l($/.0$*d$";$!"#$40#@6=560#$B+-$5"#3$
A,=65#A$ ,3$7GG$1U$./$ /0#-"$1#A,61;$!"#$-#@.3A$40#M@6=560#$B+-$6-#A$5.$-5+05$ 5"#$@6=560#$ ,3$
`T[&$ 1#A,61$ N7H$ BSC$ >#+-5$ #D50+@5?$ G;8H$ BSC$ I=6@.-#?$ 7H$ BSC$ 2+@5.4#45.3#?$ *;FH$ CSC$
#5"+3.=R;$)/5#0$Q]$"$./$I0.B5"$+5$*Y$l(?$5"#$5#14#0+560#$./$5"#$@6=560#$B+-$=.B#0#A$5.$*G$l(;$
&D40#--,.3$ B+-$ ,3A6@#A$ 2>$ +AA,3I$ I+=+@5.-#$ 5.$ +$ /,3+=$ @.3@#350+5,.3$ ./$ *H$ BSC;$ )/5#0$




3.2.3 ISOLATION OF YEAST MEMBRANES 
!"#$4#==#5$B+-$5"+B#A$+3A$0#-6-4#3A#A$,3$8G$1J$!'E%M_(=?$4_$F?8?$71J$&:!)?$G?]$J$
-.02,5.=?$ G?7$J$ O(=?$ +5$ +$ @.3@#350+5,.3$ ./$ +2.65$ *$ 1=SI$ ./$ >#+-5;$ T0.5#+-#$ ,3",2,5.0-$ B#0#$
+AA#A$5.$5"#$-6-4#3-,.3$N'.@"#$:,+I3.-5,@-?$\+-#=?$%B,5W#0=+3AR$N7$5+2=#5$./$@.14=#5#$&:!)M
/0##$+35,40.5#+-#$@.@95+,=$/.0$7GG$1=R$+3A$5"#$=>-,-$B+-$4#0/.01#A$B,5"$+$@#==$A,-0645.0$NZ3#$













3.2.4 SOLUBILIZATION OF MEMBRANE FRACTIONS  
!"#$ 5.5+=$ 40.5#,3$ @.35#35$ B+-$ #-5,1+5#A$ 2>$ 5"#$ 2,@,3@".3,3,@$ +@,A$ 40.@#A60#;$ U,I"5$
1#120+3#-$NTQR$B#0#$A,=65#A$+5$8$1IS1=$./$5.5+=$40.5#,3-$,3$5"#$40#M-.=62,=,W+5,.3$26//#0$N8G$
1J$ JZT%M!0,-$ 4_$ F?$ 7GG$ 1J$ O(=?$ *GH$ [>@#0.=$ BSC?$ 71J$ (+(=*?$ 71J$ TJ%P?$ 71J$ ^M
1#0@+45.#5"+3.=$+3A$40.5#+-#$ ,3",2,5.0-$@.@95+,=R;$)/5#0$I#35=#$-5,00,3I?$ 5"#$ =,I"5$1#120+3#$
/0+@5,.3$B+-$@#350,/6I#A$+5$*c?GGG$#)-% /.0$7$".60$+5$7G$l(;$!"#$4#==#5$B+-$5"#3$0#-6-4#3A#A$
6-,3I$ +$ T.55#0M5>4#$ ".1.I#3,W#0$ ,3$ 5"#$ -.=62,=,W+5,.3$ 26//#0$ N-+1#$ @.14.-,5,.3$ +-$ 40#M
-.=62,=,W+5,.3$26//#0R$+3A$8MA.A#@>=M^MAM1+=5.-,A#$N::JR$NA#5#0I#35S40.5#,3$0+5,.$./$Qi7R;$!"#$
-6-4#3-,.3$ N!:JR$ B+-$ 9#45$ 63A#0$ I#35=#$ -5,00,3I$ /.0$ *G$ 1,365#-$ +5$ 0..1$ 5#14#0+560#;$
E3-.=62=#$1+5#0,+=-$B#0#$0#1.C#A$2>$@#350,/6I+5,.3$/.0$7$".60$+5$7Gl($+3A$7GG?GGG$#)-;$!"#$
-64#03+5+35$@.35+,3-$5"#$-.=62,=,W#A$40.5#,3-$N%:JR;$









7;d$ J$ !M1#0@+45.#5"+3.=?$ dH$ %:%?$ 7$ 1J$ &:!)?$ Y$ J$ 60#+$ +3A$ G;G8H$ 20.14"#3.=$ 2=6#R;$
T".-4".0>=+5#A$40.5#,3-$B#0#$-#4+0+5#A$2>$#=#@50.4".0#-,-$.3$%:%$4.=>+@0,=+1>A#$I0+A,#35$





3.2.6 PURIFICATION OF HSERCA2AR863G 
T60,/,@+5,.3$ ./$ 5"#$ "%#0@+*+'Y]Q[$ 40.5#,3$ B+-$ @+00,#A$ .65$ #,5"#0$ 2>$ +//,3,5>$
@"0.1+5.I0+4">$B,5"$+C,A,3$+I+0.-#$0#-,3$ N%./5=,39$%./5$'#=#+-#$)C,A,3$'#-,3?$T0.1#I+R$+3A$
B,5"$5"#$6-#$./$+C,A,3M@.+5#A$1+I3#5,@$3+3.4+05,@=#-$NJ+I0.?$J;$#5$+=?$*G7*R;$$
E3$ 5",-$ @"+45#0?$ .3=>$ 5"#$ 40.@#A60#$ ./$ +C,A,3M+//,3,5>$ @"0.1+5.I0+4">$ ,-$ 0#4.05#A;$ P.0$
1+I3#5,@$ -#4+0+5.0$ ->-5#1$B,5"$+C,A,3M@.+5#A$1+I3#5,@$3+3.4+05,@=#-?$ -##$ 5"#$4+4#0$ ,3$ 5"#$
+44#3A,D;$
3.2.7 BATCH PURIFICATION WITH AVIDINE AGAROSE  







26//#0$ @.35+,3,3I$!"0.12,3$ NQ8G$63,5-?$ %,I1+M)=A0,@"R$ +3A$ ,3@62+5#A$.C#03,I"5$ +5$ d$ l(;$ !"#$
40.5#+-#$+@5,C,5>$B+-$-5.44#A$2>$+AA,3I$*;8$1J$TJ%P$N4"#3>=1#5"+3#-6=/.3>=/=6.0,A#R$+3A$
5"#$-64#03+5+35$B+-$5"#3$@.==#@5#A;$$
3.2.8 GEL-FILTRATION  
!"#$ +//,3,5>M460,/,#A$ "%&'()*+'Y]Q[$ .25+,3#A$ 2>$ +C,A,3$ 0#-,3$ @"0.1+5.I0+4">$ B+-$
@.3@#350+5#A$2>$X,C+-4,3M*G$N8G?GGG$JB$@65$.//?$%+05.0,6-R$+3A$+44=,#A$5.$+$%64#0A#D$*GGM_'$










3.2.9 PROTEIN RECONSTITUTION AND CRYSTALLIZATION TRIALS 
\#/.0#$ @0>-5+==,W+5,.3$ 50,+=-?$ 5"#$ -+14=#$ @.35+,3,3I$ 5"#$ %&'()*+$ 40.5#,3$ B+-$
-644=#1#35#A$B,5"$4".-4".=,4,A$:ZT($N7?*MA,.=#.>=M-3MI=,@#0.MQM4".-4".@".=,3#R$5.$0#+@"$+$
(7*&YS:ZT($0+5,.$./$Qi7$NBSBR?$7G$1J$(+(=*?$+3A$71J$)JTT(T$N!M#M1#5">=#3+A#3.-,3#M8eM
50,4".-4"+5#R;$ !"#$ -+14=#$ B+-$ #K6,=,20+5#A$ .C#03,I"5$ +5$ d$ l($ +3A$ 5"#3$ -62L#@5#A$ 5.$
6=50+@#350,/6I+5,.3$ N7YG?GGG$I+C$ /.0$7G$1,365#-R$ 5.$ 0#1.C#$+II0#I+5,.3;$(0>-5+==,W+5,.3$ 50,+=-$
B#0#$4#0/.01#A$2>$ 5"#$C+4.60$A,//6-,.3$1#5".A$ ,3$G;8$<$G;8$µ=$"+3I,3I$A0.4-$#K6,=,20+5,3I$
+I+,3-5$ 8GG$ µ=$ ./$ 26//#0$ @.35+,3,3I$ **G$ 1J$ -.A,61$ +@#5+5#?$ dH$ 5M265+3.=?$ 8$ 1J$ ^M
1#0@+45.#5"+3.=?$78H$I=>@#0.=?$YM7]H$T&[$]GGG;$
3.2.10  SODIUM DODECYL SULFATE-POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)  









3.2.11 WESTERN BLOTTING  
g#-5#03$ 2=.55,3I$ B+-$ 4#0/.01#A$ +@@.0A,3I$ 5.$ 5"#$1.A,/,#A$1#5".A$ ./$ !.B2,3$ #5$ +=;$
N!.B2,3$_;$ !;$ #5$ +=?$ 7cFcR$ )/5#0$ #=#@50.4".0#-,-?$ 5"#$ I#=$B+-$ -.+9#A$ ,3$ @.=A$ 50+3-/#0$ 26//#0$
NG;7c*$J$I=>@,3#?$*8$1J$50,-?$4_$Y;Q?$+3A$7;Q$1J$%:%R$/.0$7$"$5.$0#1.C#$%:%$+3A$+3>$#D@#--$
./$#=#@50.A#$26//#0;$)$-"##5$./$3,50.@#==6=.-#$1#120+3#$N4.0#$-,W#$G;d8$k1R$B+-$6-#A$N78$p$78$








%#0@+$ N%&'()7S*SQ$ N_QGGR$%+35+M(06W$\,.5#@"3.=.I>R$+5$+$7i8GG$A,=65,.3$ ,3$!\%$.C#03,I"5$+5$
dl($,3$+$0.@9,3I$1.5,.3;$!"#$1#120+3#$B+-$B+-"#A$Q$5,1#-$B,5"$5"#$!\%$26//#0?$@.35+,3,3I$
G;8H$!B##3$*G;$!"#$1#120+3#$B+-$ 5"#3$ ,3@62+5#A$B,5"$1.6-#$+35,0+22,5$@.3L6I+5#A$B,5"$
".0-#0+A,-"$ 4#0.D,A+-#$ /.0$ *$ "$ +5$ 0..1$ 5#14#0+560#$ ,3$ +$ 7i*GGG$ A,=65,.3$ ,3$ !\%;$ )/5#0$ +3$





3.3 RESULTS AND DISCUSSION 
3.3.1 OVER-EXPRESSION OF HSERCA2AR863G IN S. CEREVISIAE 




%&'()7+$ Nj,A#39.$ #5$ +=;?$ *GG]R;$ !",-$ "#5#0.=.I.6-$ ->-5#1$ +44#+0#A$ 5.$ 2#$ 5"#$ 1.0#$
+440.40,+5#$/.0$5"#$.C#0M#D40#--,.3$./$/63@5,.3+=$1+11+=,+3$1#120+3#$40.5#,3-?$-,3@#$2.5"$
5"#$ 4.-5M50+3-=+5,.3+=$ 1.A,/,@+5,.3$ ->-5#1$ +3A$ 5"#$ (+
*<
$ ".1#.-5+-,-$ 1#@"+3,-1$ +0#$
@.3-#0C#A$,3$>#+-5;$$
!"+39-$ 5.$ 5"#$ 4`#:T]G$ C#@5.0?$ 5"#$ "%&'()*+$ I#3#$ B+-$ ,3-#05#A$ ,3$ 5"#$ -+1#$ @.A,3I$
/0+1#$./$ !"0$ @=#+C+I#$ -,5#$ +3A$\):$ N2,.5,3$ +@@#45.0$ A.1+,3R$ -#K6#3@#-$2>$ 5"#$[+4M0#4+,0M
@=.3,3I$ N_.1.=.I.6-$ 0#@.12,3+5,.3R$ 5#@"3,K6#?$ 5.$ +==.B$ #D40#--,.3$ ./$ /6-,.3$ 40.5#,3$





%#0@+*+M\):$ ,3$ 9$% /.2.-"*").;$ U+5#0?$ +$ 4.,35$ 165+5,.3$ B+-$ I#3#0+5#A$ 5.$ 0#1.C#$ +$ /605"#0$
5"0.12,3$@=#+C+I#$-,5#$B,5",3$5"#$-#K6#3@#;$
!"6-?$5"#$0#@.12,3+35$40.5#,3$B+-$#D40#--#A$63A#0$5"#$@.350.=$./$+$I+=+@5.-#M,3A6@,2=#$
40.1.5#0?$B"#0#+-$ 5"#$ 2,.5,3>=+5,.3$ 40.@#--$ ./$ 5"#$ 40.5#,3?$ .@@600,3I$ A,0#@5=>$ ,3$ >#+-5?$ "+-$
40.C,A#A$ +$ /+-5$ +3A$ #//,@,#35$ 460,/,@+5,.3$ -50+5#I>;$ !"#$ #D40#--,.3$ ./$ 5"#$ 40.5#,3$ B+-$
4#0/.01#A$#,5"#0$ ,3$ +$".1#$1+A#$2,.0#+@5.0$ NP,I60#$QR$ .0$ ,3$ *$ =$ /=+-9-$ @.35+,3,3I$#+@"$3.5$
1.0#$ 5"+3$8GG$1=?$ +@@.0A,3I$ 5.$ 5"#$40.5.@.=$ 0#4.05#A$2>$(+0A,;$ N(+0A,?$:;$ #5$ +=?$ *G7GR;$g#$
B#0#$+2=#$5.$0#@.C#0$+2.65$8G$I0+1-$./$>#+-5$/.0$=,5#0$./$@6=560#;$%,3@#$,3$C,C.$5"#$2,.5,3>=+5,.3$






















!"#$% Z$%X.*0.28% H(10% )8)(K*"*% 14% 42)/0"18*% 421+% 05.%+.+H2)8.% 72.7)2)0"18% HK% 3*"8#% )-","8CU;'% 721H.$% =((% 05.%
H"10"8K()0.,%7210."8*%W.2.%,.0./0.,%HK% 05.%721H.G% 2.-.)("8#% 0W1%.8,1#.813*%H"10"8K()0.,%7210."8*%.672.**.,% "8%
K.)*0% [7327(.% )221W*\$% 9)+7(.*% W.2.% (1),.,% )*% *51W8% H.(1W]% P<:G% 010)(% /23,.% .602)/0I% '&G% 7.((.0% &I% 9&G%
*37.28)0)80%&I%'>G%7.((.0%>G%/122.*718,"8#%01%05.%5"#5%+.+H2)8.*I%9>G%*37.28)0)80%>I%'AG%7.((.0%>G%/122.*718,"8#%
01% 05.% ("#50% +.+H2)8.*I% 9AG% *37.28)0)80% A% )8,%^G% +1(./3()2% W."#50% +)2L.2$% P5.% K.)*0% H"10"8K()0.,% 7210."8*%





[(.40\% )8,%)3012),"1#2)+% [2"#50\% 14% 05.% `aCAA'b%=P'C751*7512K()0.,%59.2/)>);?@AB%+.+H2)8.*% "8% 72.*.8/.% 14%
N$&%+^%<)<(>%[M)8.%&\G%_N%+^%:BP=%[M)8.%>\G%&c^%P5)7*"#)2#"8%[M)8.%A\$%%%





3.3.2 HUMAN SERCA, ISOFORM 2A, PURIFICATION  
)2.65$d$U$./$>#+-5$@6=560#$B#0#$6-#A$/.0$#+@"$460,/,@+5,.3$50,+=?$/0.1$B",@"$+2.65$*GG$I$
./$A0>$@#==$4#==#5$B+-$0#@.C#0#A;$!"#$#-5,1+5#A$5.5+=$40.5#,3$@.35#35$ ,3$ 5"#$ =,I"5$1#120+3#$
/0+@5,.3$B+-$+2.65$*]$1I;$
%,3@#$ 0#@.12,3+35$ "61+3$ %&'()*+$ N"%&'()*+'Y]Q[M\):R$ @.14#5#-$ B,5"$ 5"#$
#3A.I#3.6-$2,.5,3>=+5#A$40.5#,3-$/.0$5"#$2,3A,3I$5.$+C,A,3?$+3$+AA,5,.3+=$460,/,@+5,.3$-5#4$B+-$
0#K6,0#A$,3$.0A#0$5.$,3@0#+-#$5"#$0#@.C#0>$./$5"#$0#@.12,3+35$40.5#,3;$&=65,.3$./$5"#$40.5#,3$
B+-$+@",#C#A$2>$.C#03,I"5$ ,3@62+5,.3$./$ 5"#$40.5#,3M2.63A$0#-,3$B,5"$ 5"0.12,3;$!"#$ /6-,.3$





+=-.$ A#5#@5#A$ 2>$g#-5#03$ 2=.5$ +3+=>-#-$B,5"$ 0+22,5$ 4.=>@=.3+=$ +35,M%&'()$ NP,I60#$ FR$ +3A$ ,-$
5"#0#/.0#$ +550,265+2=#$ 5.$ "%&'()*+'Y]Q[;$ !"#$ A,//#0#3@#$ 2#5B##3$ 5"#$ +44+0#35$1.=#@6=+0$
B#,I"5$./$460,/,#A$%&'()*+'Y]Q[$NYG$9:+R$+3A$5"#$#D4#@5#A$B#,I"5$0#4.05#A$,3$5"#$=,5#0+560#$
N778$9:+R$,-$+550,265+2=#$5.$5"#$#//#@5$./$5"#$A#5#0I#35$.3$5"#$#=#@50.4".0#5,@$1.2,=,5>$./$5"#$
40.5#,3$ ,3$ %:%MT)[&?$ +-$ ./5#3$ 0#4.05#A$ /.0$ ">A0.4".2,@$ 40.5#,3-$ ,3$ 5"#$ 40#-#3@#$ ./$
A#5#0I#35-$N'+5"?$);$#5$+=?$*GGcR;$P,3+==>?$+$I#=M/,=50+5,.3$-5#4$NP,I60#-$Y$+3A$cR$B+-$4#0/.01#A$
5.$ ,3@0#+-#$ 40.5#,3$ 460,5>$ +3A$ 5.$ #D@"+3I#$ 5"#$ A#5#0I#35$ /.0$ @0>-5+==,W+5,.3$ 50,+=-;$ !"#$ /,3+=$
>,#=A$B+-$+2.65$8GG$kI$./$FGH$460,/,#A$40.5#,3;$!"#$+1.635$./$0#@.12,3+35$0+22,5$%&'()M7+$
















!"#$% d$% '32"4"/)0"18% 14% 59:;<=>);?@AB% HK% )-","8% )44"8"0K% /521+)01#2)75K$%X.*0.28% H(10% )8,% "++381,.0./0"18%
3*"8#%)80"C9:;<=&e>eA%)80"H1,K$%9)+7(.*%412%9E^%01%;:9%42)/0"18*%W.2.%>NC41(,G%.(30.,%42)/0"18*%*)+7(.*%[:\%W)*%
711(.,%)8,%_NC41(,$%%







!"#$% ?$% 9:<C!'M<%732"4"/)0"18% *0.7% 412% /2K*0)(("V)0"18%)00.+7*$% P5.% .(30"18%7214"(.% )0% >?N%8+%14% 59:;<=>);?@AB%





!"#$% f$% 9:<C!'M<% 732"4"/)0"18% *0.7% 412% /2K*0)(("V)0"18% )00.+7*$% <11+)**".% H(3.% *0)"8"8#% 9E9C'=B:% 14% 05.% .(30.,%








A0.4$ C+4.60MA,//6-,.3$ 5#@"3,K6#;$ a3/.0563+5#=>?$ -.$ /+0$ B#$ +0#$ 3.5$ +2=#$ 5.$ .25+,3$ -6,5+2=#$
@0>-5+=-$/.0$A,//0+@5,.3$+3+=>-,-;$
3.4 CONCLUSIONS 
:#-4,5#$ -,I3,/,@+35$ +3A$ @.3-,A#0+2=#$ 0#@#35$ ,140.C#1#35-?$ 5"#$ #D40#--,.3$ +3A$ 5"#$
-62-#K6#35$ 460,/,@+5,.3$ ./$ /63@5,.3+==>$ /.=A#A$1#120+3#$ 40.5#,3-$ ,3$ -6//,@,#35$ +1.635-$ /.0$
/63@5,.3+=$+3A$ -506@560+=$ -56A,#-$ ,-$ -5,==$ +$ @"+==#3I,3I$ 5+-9q$B#$6-#A$ 5"#$40.4.-#A$ ->-5#1$ 5.$
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ABSTRACT: We report on the surface characterization, functionalization, and
application of stable water suspensions of novel surface active maghemite
nanoparticles (SAMNs), characterized by a diameter of 11 ± 2 nm and
possessing peculiar colloidal properties and surface interactions. These features
permitted the acquisition of titration curves and aqueous UV−vis spectra and
suggested a role played by surface under-coordinated iron atoms. This new class
of nanoparticles was obtained through an easy, inexpensive, one-step, green
procedure and functionalized with ligands of high biotechnological interest, such
as biotin and avidin, by simple incubation in aqueous solution. Bound avidin was
determined by measuring the disappearance of free avidin absorbance at 280 nm,
as a function of increasing nanoparticle concentration, showing the presence of
10 ± 3 avidin molecules per nanoparticle. The biological activity of the SAMN@
avidin complex was evaluated and the number of available biotin binding sites was
determined, using biotinyl-ﬂuorescein as a probe, showing that each bound avidin
molecule is able to bind 2.8 ± 0.8 biotin molecules, conﬁrming the maintenance of biological activity and excellent binding
capacity of the SAMN@avidin complex. Furthermore a Langmuir isotherm model was used to describe the biomolecule speciﬁc
monolayer adsorption onto the particle surface, and in the case of avidin, the maximum adsorption capacity was 100 ± 27 μg
avidin/mg SAMN, whereas the binding constant is 45.18 μL μg−1. The SAMN@avidin complex was characterized by UV−vis
spectroscopy, quartz crystal microbalance, FTIR spectroscopy, and transmission electron microscopy. Finally, SAMN@avidin
was applied for the large scale puriﬁcation of recombinant biotinylated human sarco/endoplasmic reticulum Ca2+-ATPase
(hSERCA-2a), expressed by Saccharomyces cerevisiae. The protein was magnetically puriﬁed, and about 500 μg of a 70% pure
hSERCA-2a were recovered from 4 L of yeast culture, with a puriﬁcation yield of 64%.
■ INTRODUCTION
The combination of nanotechnology, biochemistry, biotechnol-
ogy, and molecular biology has developed into an emerging
research area: nanobiotechnology, which oﬀers exciting
opportunities for developing new nanosized materials and
technologies. In order to develop new hybrid nanostructures it
is mandatory to understand surface nanostructure properties.
Furthermore, hybrid nanostructures, which combine magnetic
nanoparticles with bioelements, such as antibodies, proteins, or
other functionalities, lead to superparamagnetic biofunctional
nanoparticles exhibiting highly selective binding. As a result,
these nanoparticles could have many applications in biology
and medicine, including drug delivery, medical imaging, and
protein puriﬁcation.1,2
Recently, a number of aqueous magnetic nanoparticle
dispersions have been reported, all coated by low or high
molecular weight organic polymers or inorganic shells as steric
stabilizers in order to prevent the particle aggregation and to
maintain long-term stability, pH and electrolyte tolerance, and
proper surface chemistry. Many of the polymeric stabilizers
reported only bind weakly to nanoparticle surfaces and
eventually desorb or exchange with bulk solution, aﬀecting
the stability of the resultant dispersions. Furthermore, processes
to coat nanoparticles are often cumbersome, time-consuming,
expensive, and with low yield and limiting massive productions.
At last, nanoparticle coating reduces the average material
magnetic moment by introducing nonmagnetic material in the
ﬁnal nanoparticles.3,4
Recently, we developed a novel synthesis of nanostructured
superparamagnetic material, totally carried out in water,
without any organic solvent or surfactant.5,6 A wet reaction
oﬀers several advantages: simplicity, low cost, and high yield
scale and, above all, it is an organic solvent free process and
thus ecologically green. This nanomaterial is composed of
Received: August 3, 2012
Revised: October 5, 2012
Published: October 11, 2012
Article
pubs.acs.org/Langmuir
© 2012 American Chemical Society 15392 dx.doi.org/10.1021/la303148u | Langmuir 2012, 28, 15392−15401
stoichiometric maghemite (γ-Fe2O3), with peculiar surface
chemical behavior, called SAMNs (surface active magnetic
nanoparticles).5,6 SAMNs are synthesized in the dimension
range around 10 nm without any superﬁcial modiﬁcation or
coating derivatization. Bare SAMNs are dispersible in water,
and their suspensions are stable for several months. Because of
their unique physical and chemical properties, these bare iron
oxide nanoparticles present a high average magnetic moment
and can be easily used to immobilize speciﬁc organic
molecules.6 Functionalization is carried out in water, without
any chemical reactant, and the total derivatization process is
mild, minimizing alteration of ligand macromolecular structure,
low cost, and ecologically green. In the present manuscript,
SAMN surface properties were studied by titration curves, UV−
vis spectroscopy, and ferrocyanide absorption, and we
attributed the main responsibility in the distinctive SAMNs
surface chemistry to under-coordinated iron atoms.
In biosciences and biotechnology, the isolation of proteins
and peptides is usually performed using a variety of
chromatographic, electrophoretic, ultraﬁltration, or precipita-
tion techniques, with aﬃnity chromatography being the most
important. Currently, aﬃnity ligand techniques represent the
most powerful tool available to the downstream processing
both in terms of selectivity and recovery. The strength of
column aﬃnity chromatography has been shown in thousands
of successful applications, especially in the laboratory scale.7
However, the disadvantage of all standard column liquid
chromatography procedures is the impossibility to cope with
samples containing particulate material, so this technique is not
suitable for work in early stages of the isolation/puriﬁcation
process, where suspended solid and fouling components are
present in the sample.8 Among the existing protein puriﬁcation
protocols, magnetic separation and puriﬁcation seem to be
convenient methods for selective and reliable capture of speciﬁc
proteins.4−9 Magnetic separation techniques have several
advantages in comparison with standard separation procedures.
These processes are usually very simple, with only a few
handling steps. All of the puriﬁcation steps can take place in
one single test tube or vessel, even on very large volumes.
There is no need for expensive liquid chromatography systems,
centrifuges, ﬁlters, or other equipment. The separation process
can be performed directly on crude samples, containing
suspended solid material. Furthermore, separation of target
proteins using standard chromatography techniques often leads
to large volumes of diluted protein solutions. In this case,
appropriate magnetic particles can be used for target protein
concentration, instead of ultraﬁltration, precipitation, etc.9
In order to propose a biotechnological application of
SAMNs, we functionalized their surface with ligands of high
biotechnological interest, such as biotin and avidin. Biotin and
avidin represent an example of a molecular key-lock system in
life processes, and their most important feature consists of the
speciﬁcity and the strength of their interaction (Ka ≈ 1015
M−1). We tested the functionality of SAMN@biotin and
SAMN@avidin nanostructures, toward avidin and biotin,
respectively. Subsequently, we applied the SAMN@avidin
system for the puriﬁcation of the recombinant sarcoplasmic
reticulum Ca2+-ATPase (SERCA-2a). This membrane protein,
belonging to the family of P-types ATP-ases, plays a crucial role
in the regulation of the excitation-contraction coupling in
skeletal and cardiac muscle, thus making it an important target
for research investigations.
■ MATERIALS AND METHODS
Chemicals. Chemicals were purchased at the highest commercially
available purity, and they were used without further treatment.
Iron(III) chloride hexahydrate (97%), sodium borohydride (NaBH4),
tetramethylammonium hydroxide (TMA), biotin, perchloric acid,
biotinylated ﬂuorescein, phenylmethanesulfonylﬂuoride (PMSF), and
ammonia solution (35% in water) were obtained from Aldrich (Sigma-
Aldrich, Italy). Egg’s Avidin (cat. A9275; purity ≥98%) was from
Aldrich (Sigma-Aldrich, Italy)
Instrumentation. Optical spectroscopy and ﬂuorescence measure-
ments were respectively performed in 1 cm quartz cuvettes using a
Cary 50 spectrophotometer and a Cary Eclipse ﬂuorescence
spectrometer (Varian Inc., Palo Alto, CA, U.S.A.).
FT-IR spectra were acquired using a Thermo Nicolet Nexus 670
instrument. Nanoparticle samples were lyophilized, homogenized with
KBr powder, and pelleted by an 8.0 tons hydraulic press.
Nanoparticles (2 g L−1) were suspended in Milli-Q grade water (3.5
L) by treatment in an ultrasonic bath at 48 kHz, 50 W (Bransonic,
mod. 221 at 48 kHz, 50 W), for at least 3 h, giving a stable colloidal
suspension.
Microscopic characterizations of the native maghemite particles, as
well as biotin and avidin coated particles, were performed by
transmission electron microscopy (TEM) using a FEI Tecnai 12
microscope operating at 120 kV with a point-to-point resolution of 1.9
Å. Before measurements, SAMN were dispersed in ethanol (50 mg
L−1), and the suspension was treated by ultrasound for 10 min. A drop
of a very dilute suspension was placed on a carbon-coated copper grid
and allowed to dry by evaporation at room temperature.
Quartz crystal microbalance (QCMagic), from Elbatech (Marciana,
LI, Italy), was interfaced to a driving PC by means of a USB port.
QCMagic was equipped with a low-volume (20 μL) ﬂow-through
reaction chamber, which houses the oscillating crystal, tuned to work
at 9.5 MHz.
Derivatization of the Piezoelectric Crystal. Piezoelectric
crystals (Elbatech, Marciana, LI, Italy) consist of a thin quartz disk
with gold electrodes plated on it, in which the acoustic wave
propagates in a direction perpendicular to the crystal surface. As
shown by Sauerbrey in 1959,10 changes in resonant frequency are
simply related to the mass accumulated on the crystal by the following
equation:
η ρΔ = − Δf mnf2 0
2
q q (1)
where ηq and ρq are the density and the viscosity of the quartz, n is the
overtone number, f 0
2 is the basic oscillator frequency of the quartz,
and Δm is the mass adsorbed on the surface per unit/area. For an AT-
cut quartz crystal, Δf = −2.26 × 10−6 f 02Δm.
Before the immobilization, the electrode surface of the quartz crystal
was cleaned with ethanol and Milli-Q water. The gold electrodes,
plated on piezoelectric crystals, were derivatized as follows: freshly
cleaned crystals were immersed in an unstirred ethanolic solution of 10
mM 2-mercaptoethylamine at room temperature, in the dark, for 14 h.
Crystals were then washed with ethanol and Milli-Q water to remove
the excess of the thiol. In order to immobilize biotin on amine
derivatized piezoelectric crystals, carbodiimide chemistry was used. In
particular, amine modiﬁed crystals were incubated in the presence of
10 mM biotin, 50 mM N-hydroxysuccinimide, and 200 mM EDC in
water for 2 h. This solution must be prepared immediately before the
use. The crystals were ﬁnally washed with Milli-Q water to remove the
excess of reactants.
Derivatized piezoelectric crystals were inserted in a ﬂow injection
analysis system (P-500 pump, MV-7 injection valve and LC-500
controller by Pharmacia, Uppsala, Sweden), equipped with a 200 μL
loop, at a ﬂow rate of 100 μL min−1. In this way, a QCM sensor,
bearing solvent exposed biotin molecules on the surface, was prepared.
The biotin modiﬁed sensor was tested with SAMN@avidin complex.
Alternatively, by injecting an avidin solution (50 μg/mL) in the ﬂow
QCM system, containing the biotinylated crystal, the crystal surface
was covered by a monomolecular layer of avidin. Due to the presence
of 4 biotin binding sites on avidin molecules, the resulting crystal
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surface exposed biotin binding sites to the solvent.11,12 In this last case,
the avidin modiﬁed sensor was tested with SAMN@biotin complex.
Synthesis of SAMNs. A typical nanoparticles synthesis was already
described5,6 and can be summarized as follows: FeCl3·6H2O (10.0 g,
37 mmol) was dissolved in Milli-Q grade water (800 mL) under
vigorous stirring at room temperature. NaBH4 solution (2 g, 53 mmol)
in ammonia (3.5%, 100 mL, 4.86 mol/mol Fe) was then quickly added
to the mixture. Soon after the reduction reaction occurrence, the
temperature of the system was increased to 100 °C and kept constant
for 2 h under stirring. The material was cooled at room temperature
and aged in water, as prepared, for other 12 h. This product was
separated by imposition of an external magnet, as described in
Method, for 60 min, and washed several times with water. This
material can be transformed into a red brown powder (ﬁnal synthesis
product) by drying and curing at 400 °C for 2 h, obtaining individual
nanoparticles after thermal treatment. The resulting nanopowder
showed a magnetic response upon exposure to a magnetic ﬁeld. The
ﬁnal mass of product was 2.0 g (12.5 mmol) of Fe2O3 and a yield of
68% was calculated.
The obtained nanomaterial was characterized by zero ﬁeld and in
ﬁeld (5 T) Mössbauer spectroscopy, FTIR spectroscopy, high
resolution transmission electron microscopy, XRPD, magnetization
measurements5,6 and resulted constituted of stoichiometric maghemite
(γ-Fe2O3) with a mean diameter of 11 ± 2 nm (see Figure S1), which
can lead to the formation, upon sonication in water (Bransonic, model
221, 48 kHz, 50 W) of a stable colloidal suspension, without any
organic or inorganic coverage. Notwithstanding, the surface of these
bare maghemite nanoparticles shows peculiar binding properties and
can be reversibly derivatized with selected organic molecules. We
called these bare nanoparticles suface active maghemite nanoparticles
(SAMNs).
Magnetic Separation. A series of Nd−Fe−B magnets (N35,
263−287 kJ/m3 BH, 1170−1210 mT ﬂux density by Powermagnet,
Germany) were used for the magnetic separations. Magnets were
applied on the bottom of the reaction ﬂasks, and depending on the
ﬂask volume, supernatants were separated by suction after 30−60 min.
Derivatization of SAMNs with Avidin. SAMNs can be
superﬁcially derivatized by simple incubation in water solutions in
the presence of avidin. In the present case avidin binding was carried
out in 50 mM tetramethylammonium perchlorate, pH 7.0. The
amount of bound avidin was calculated from the disappearance of the
absorbance at 280 nm in the supernatants (ε280nm = 6.99 × 104 M−1
cm−1). Alternatively, bound avidin was released from nanoparticle
surface by treatment with 0.5 M ammonia. The released protein was
evaluated by spectrophotometry.
Heterologous Expression of Human SERCA-2a in S.
cerevisiae. The c-DNA coding for human SERCA-2a (Imagenes
GmbH, Berlin, Germany) was ampliﬁed by PCR and cloned into
pYeDP60 plasmid (kindly provided by Marc le Maire, (Universite ́
Paris-Sud, F-91405 Orsay, Institut de Biologie et Technologies de
Saclay (iBiTec-S) Gif-sur-Yvette, and URA CNRS, France) in the
same coding frame of thrombin cleavage site and BAD (biotin
acceptor domain) sequences. A mutant of hSERCA-2a (R863G) was
generated by PCR based on the QuickChange site-directed muta-
genesis strategy (Stratagene) to eliminate a thrombin cleavage site
within the protein sequence.
Competent S. cerevisiae cells (strain W303.1b Gal4−2 (a, leu2, his3,
trp1::TRP1-GAL10-GAL4, ura3, ade2−1, canr, cir+) were transformed
with the pYeDP60 vector containing hSERCA-2a (R863G) and
selected on minimal plates as described by Gietz and Woods.13
Protein Expression. A total of 10 mL of minimal medium (0.1%
w/v Bacto Casamino acids (BD Diagnostic Systems, NJ, U.S.A.), 0.7%
w/v yeast nitrogen base, 2% w/v glucose, 20 μg/mL adenine) were
inoculated with the selected clone and incubated at 28 °C for 24 h.
The preculture was then diluted in 100 mL of fresh medium. The
second preculture was used to start the culture in YPGE medium (1%
w/v yeast extract, 0.5% w/v glucose, 1% w/v bactopeptone, 2.7% v/v
ethanol). After 36 h of growth at 28 °C, the temperature of the culture
was lowered to 20 °C. Expression was induced by adding galactose to a
ﬁnal concentration of 2% w/v. After overnight incubation at 20 °C, an
additional induction with galactose was performed. The culture was
stopped after 6 h.14
Isolation and Solubilization of Membrane Fractions.
Membranes were separated as described by Cardi et al.15 and the
total protein content was estimated by the bicinchoninic acid
procedure.16 Protein solubilization was performed in a buﬀer
containing 50 mM MOPS-Tris, pH 7.0, containing 100 mM KCl,
20% v/v glycerol, 1 mM CaCl2, 1 mM PMSF, 1 mM 2-
mercaptoethanol, complete EDTA-free antiprotease cocktail (Roche
Diagnostics, Basel, Switzerland) and n-dodecyl-β-D-maltoside (DDM)
(detergent/protein ratio of 3:1). The suspension was kept under
gentle stirring for 20 min at room temperature. Insoluble materials
were removed by centrifugation at 100,000g.
Puriﬁcation of hSERCA-2a and Its Mutant. The supernatant
(180 mL) was mixed with SAMN@avidin (40 mL, 3.12 g/L) and
gently stirred overnight at 4 °C. The magnetic nanoparticles were
separated by exposure to an external magnet for 1 h at 4 °C and
washed twice with 80 mL of buﬀer containing 0.05 M Tris, pH 7.0, 1
M NaCl, 20% (w/v) glycerol, 1 mM CaCl2, 1 mM 2-mercaptoethanol,
and 0.05% w/v DDM) to remove nonspeciﬁcally bound proteins. A
further washing step was carried out with 80 mL of the buﬀer
containing 0.05 M Tris-HCl, pH 7.0, containing 0.15 M NaCl, 20% v/
v glycerol, 2.5 mM CaCl2, 1 mM 2-mercaptoethanol, 0.05% w/v
DDM. The removal of the BAD domain was achieved by thrombin
cleavage. The protease activity was stopped by adding 2.5 mM PMSF
(phenylmethanesulfonylﬂuoride). The nanoparticles were removed by
magnetic separation.
Gel-Filtration. The aﬃnity-puriﬁed hSERCA-2a, obtained by
SAMN@avidin puriﬁcation, was concentrated by Vivaspin-20 (50
000 Mw cut oﬀ, Sartorius) and applied to a Superdex 200-HR 10/300
(GE Healthcare Bio-Sciences, Uppsala, Sweden) at 0.5 mL/min. The
solvent was constituted of 50 mM Mops-Tris, pH 7.0, containing 100
mM KCl, 20% glycerol, 1 mM CaCl2, and 0.5 g L
−1 dodecylocta-
ethylene glycol ether. The gel-ﬁltration was performed in order to
increase the protein purity.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophore-
sis (SDS-PAGE). SDS-PAGE was performed as described by
Laemmli,17 using a 12% polyacrylamide gel in a vertical slab gel
apparatus (Hoefer Scientiﬁc Instrument). Protein samples were
prepared in a denaturing sample buﬀer containing 1.4 M 2-
mercaptoethanol, 8 M urea and 1 mM EDTA. The samples (20 μL)
were diluted in an equal volume of denaturing sample buﬀer and
boiled at 100 °C for 1 min. Electrophoresis was performed at 120 mA
and 25 mA for 1 h. The run was stopped when the dye front was 2 to 3
mm away from the bottom edge of the gel. The gel was then stained
using the Coomassie Brilliant Blue (0.05% Coomassie blue R, 40%
methanol, 10% acetic acid).18 Destaining was performed by washing
the gels several times with either water or 10% acetic acid.
Western Blotting. Western blotting was performed according to
the modiﬁed method of Towbin et al.19 After electrophoresis, the gel
was soaked in cold transfer buﬀer (0.192 M glycine, 25 mM tris, pH
8.3, and 1.3 mM SDS) for 1 h to remove SDS and any excess of
electrode buﬀer. A sheet of nitrocellulose membrane (pore size 0.45
μm) was used (15 × 15 cm) and then was immersed into the transfer
buﬀer. To avoid contamination, forceps and gloves were used when
handling the membrane.
Proteins transfer was obtained with a Mini-Trans-Blot Electro-
phoretic transfer Cell (Bio-Rad) at 100 V and 350 mA for 2 h. After
the transfer, the nitrocellulose membrane was gently rocked in
blocking buﬀer constituted of 3% (w/v) BSA in TBS buﬀer (20 mM
Tris-HCl, pH 7.6, 150 mM NaCl) for 2 h at room temperature to
block unoccupied sites. The membrane was then incubated with
polyclonal antibody anti Serca (SERCA1/2/3 (H300) Santa-Cruz
Biotechnology) at a 1:500 dilution in TBS overnight at 4 °C in a
rocking motion. The membrane was washed 3 times with the TBS
buﬀer, containing 0.5% Tween 20. The membrane was then incubated
with mouse antirabbit conjugated with horseradish peroxidase for 2 h
at room temperature in a 1:2000 dilution in TBS. After an additional
washing step (3 times with TBS and 0.5% Tween 20), the bound
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antibodies were revealed with Amersham ECL reagent (GE Helthcare
and Life Science) in a Kodak Image Station 4000MM Pro (Kodak).
■ RESULTS
In order to characterize the surface of nanomaterials and to
propose new nanobiotechnological applications, it is of
fundamental importance to work with stable colloidal water
suspensions and the excellent colloidal behavior of SAMNs
permitted some informative characterizations. In the present
case, maghemite nanoparticles (SAMNs), synthesized accord-
ing to an innovative, already described method,5,6 were used.
The synthetic mechanism of maghemite formation under our
experimental conditions, brieﬂy described in the Materials and
Methods section, comprises the reduction of iron(III) by
borohydride in water, leading to zerovalent iron. The reaction is
conducted in an ammonia containing, alkaline solution, which
generates very easily an unstable intermediate. This inter-
mediate, right after its formation, is heated at 100 °C and aged
in water, giving maghemite nanoparticles, with no traces of
other iron compounds. After curing this material at 400 °C, we
obtain the ﬁnal product, characterized for being stoichiometric
crystalline maghemite nanoparticles with peculiar surface
properties. The synthetic mechanism of maghemite formation
under our experimental conditions is under detailed study.
The resulting nanoparticles were suspended in bidistilled
water by using an ultrasonic bath (Bransonic, model 221 at 48
kHz, 50 W). Once formed, this colloidal suspension of bare
maghemite nanoparticle was stable, without precipitation or
aggregation phenomena, for more than 6 months, in contrast
with other maghemite nanoparticles described in literature.20,21
The remarkable aqueous suspensions stability of SAMNs was
exploited to obtain information on nanoparticle surface
behavior by pH titration. An aliquot of SAMN colloidal water
suspension (50 mL, 200 mg/L) was brought at pH above 10.5
with tetramethylammonium hydroxide and retro-titrated with 1
M perchloric acid. Two diﬀerent pKa were evidenced (pKa1 =
5.0 and pKa2 = 8.5), demonstrating the presence of diﬀerent
ionizable groups on SAMN surface, diﬀerently to data reported
in literature.22 From the same titration curve, 2.5 meq/g
SAMNs for each ionizable group were estimated.
In order to obtain deeper information on the nature of
nanoparticle surface, SAMNs (500 mg/L) were suspended in
0.10 M K4Fe(CN)6 (50 mL) and stirred for about 30 min.
Then, under continuous stirring, few drops of 6 M HCl were
added, till pH 3.5. The resulting mixture turned to blue in few
seconds (see Figure 1A), forming the typical Prussian blue
color, demonstrating the presence of under-coordinated Fe3+
functionalities on SAMN surface. In Figure 1B, the UV−vis
spectrum of bare and Fe(CN)6
4‑ modiﬁed SAMNs is presented.
The electronic absorption spectrum of bare SAMNs, acquired
in water, shows a wide band with a maximum at about 400 nm
(Figure 1B) characterized by an extinction coeﬃcient of 1520
M−1cm−1, expressed as Fe2O3 molar concentration. Further-
more, we noticed that optical properties of SAMNs depend on
the presence of salts and on the pH of the suspension. In fact,
the SAMN UV−vis spectrum acquired in 50 mM tetramethy-
lammonium perchlorate, pH 7.0, resulted diﬀerent from the
spectrum acquired in pure water see Figure 2A. The SAMN
spectrum in tetramethylammonium perchlorate, pH 7.0, shows
a wide absorption band characterized by two peaks, at 450 and
500 nm, respectively. Optical properties of SAMN suspensions
were also analyzed as a function of pH, in the 200−800 nm
spectral range. It was noticed that the wavelength of the
absorption maximum was constant, at 450 nm, in the 3.5 − 8.8
pH range, and it decreased to 380 nm increasing the pH value
from 8.0 to 11.0 (see Figure 2B). The second peak, at 500 nm,
gradually disappears with the increasing of pH, conﬁrming the
involvement of surface properties on optical SAMN behavior.
SAMN Surface Functionalization with Biotin and
Avidin. SAMN surface functionalization was accomplished
with biotin and avidin by simple incubation of reactants in 50
mM tetramethylammonium perchlorate, at pH 7.0. In
particular, SAMN colloidal dispersion (50 mg/L) were
incubated with avidin (100 mg/L) or biotin (100 μM), under
overnight end-over-end mixing at 4.0 °C. After the incubation
period, nanoparticles were separated by the application of an
external magnetic ﬁeld and the presence of the biomolecule in
the supernatant was checked by spectrophotometry. SAMN@
biotin or SAMN@avidin complexes were magnetically isolated
and washed several times with 50 mM tetramethylammonium
perchlorate, pH 7.0, and water. Biomolecule coverage on
SAMNs was stable, without any loss in solution of biotin or
avidin, as checked by spectrophotometry. Even the interaction
of avidin and biotin with SAMN surface produced an alteration
of nanoparticle optical properties. In this case, both the shape
and the position of maximum absorption were altered, further
demonstrating the inﬂuence of SAMN surface properties on
optical characteristics. In water, SAMN@avidin presents a
Figure 1. SAMNs superﬁcially derivatized with Fe(CN)6
4‑. Photograph
of bare SAMNs and SAMN@Fe(CN)6
4‑ suspensions. Optical
spectrum of bare SAMN and SAMN@Fe(CN)6
4‑ suspension acquired
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single broad absorption peak, red-shifted by about 10 nm with
respect to bare SAMNs, whereas the spectrum of SAMN@
biotin is characterized by two peaks, at 450 and 510 nm (see
Figure S2).
SAMN@biomolecule complexes were also studied by
transmission electron microscopy (TEM) and FTIR. TEM
microscopy images of the SAMN@biotin complex indicate the
presence of an organic matrix, as a 2−3 nm sized shell around
iron oxide nanoparticles, characterized by a lower electron
density, attributable to biotin bound molecules on the SAMN
surface.
SAMN@biotin complex was characterized by FTIR spec-
troscopy and compared with underivatized SAMNs. A
remarkable change in the FTIR spectrum of SAMNs upon
biotin binding, recorded in the 400−4000 cm−1 range, conﬁrms
the binding of biotin on the SAMN surface (see Figure 3). The
FTIR spectrum of free biotin shows two strong bands in the
region around 1700 cm−1: The most intense band at 1706 cm−1
is assigned to the asymmetric CO stretching of the
protonated carboxylate group, whereas the band at 1684
cm−1 is due to the CO stretching vibration of the ureido
group.23,24 It can be observed that the IR spectrum of the
SAMN@biotin complex does not show any of the two IR
bands, suggesting that both the carboxyl terminal group of the
valeric acid chain and the carbonyl of the ureido group are
involved in the binding,25 possibly with under-coordinated
iron(III) sites, as discussed by Chen and co-workers.26
As a low molecular weight ligand, such as biotin, could
completely adhere to the surface of nanoparticles, hindering its
recognition by avidin, SAMN@biotin complex was tested by
quartz crystal microbalance (QCM). In this case, the gold
surface of the piezoelectric crystal was derivatized with avidin,
then 50 μg/mL SAMN@biotin complex was injected in the
QCM ﬂow-through system. No variation of the resonance
frequency acquired by QCM was observed, conﬁrming that the
binding capacity of SAMN@biotin toward avidin was
compromised, and bound biotin cannot be recognized by
avidin, as suggested by FTIR measurements. The unavailability
of bound biotin for avidin binding lead us to exclude SAMN@
biotin for the development of any further application.
SAMN@avidin complex was prepared as already described
and characterized by TEM, FTIR spectroscopy and QCM.
TEM images of SAMN@avidin showed the presence of an
organic shell coverage around the iron oxide nanoparticle (see
Figure 4), characterized by a shell thickness of about 5 nm, and
a lower contrast of particles themselves, which are more
embedded in the organic matrix. The shell thickness is in good
agreement with avidin size (5.6 × 5.0 × 4.0 nm).27 The
aggregation phenomenon showed by the coated nanoparticles
is probably due to TEM sample pretreatment and drying on the
copper grid. In water suspensions SAMN@avidin still maintain
their stable colloidal behavior.
From the FTIR spectrum of SAMN@avidin (see Figure 5),
the presence of typical IR bands, attributable to protein
vibrational frequencies of CC, CO, and CH2− groups, in
the 1000−1700 cm−1 range, appeared,28 conﬁrming the
presence of avidin bound on nanoparticle surface. In particular,
the characteristic protein amide I and amide II IR bands at 1654
Figure 2. Optical spectrum of SAMN suspension. Spectrum of
nanoparticles (50 mg/L), dispersed by sonication, acquired in a 1 cm
quartz cuvette. (---) SAMN in water, pH 7.0; (―) SAMN in 50
mM tetramethylammonium perchlorate, pH 7.0. Dependence of the
wavelength of maximum absorption of a nanoparticle colloidal
dispersion as a function of pH. Nanoparticle colloidal dispersion
(100 mg/L) was prepared in 50 mM tetramethylammonium
perchorate. The pH was controlled by small additions of perchloric
acid and tetramethylammonium hydroxide.
Figure 3. FTIR spectrum of the SAMN@biotin complex. Nano-
particles samples were lyophilized, homogenized with KBr powder and
pelleted by an 8.0 tons hydraulic press. (―) SAMN, (---) biotin,
and (····) SAMN@biotin. Inset: Detail of the FTIR spectrum of
SAMN@biotin complex.
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and 1544 cm−129 are present in the SAMN@avidin FTIR
spectrum (see Figure 5).
As the interactions between proteins and solid surfaces could
lead to signiﬁcant changes in protein structure30 and,31 possibly
altering protein functionality and biological activity, as well as
modifying ligand accessibility due to unproper orientation of
bound protein, SAMN@avidin binding properties were tested
by quartz crystal microbalance (QCM), in which the gold
surface of the piezoelectric crystal was derivatized with biotin,
as described in Methods. Upon injection of 100 μL of 100 mg
L−1 SAMN@avidin suspension in the ﬂow-through QCM
system, a 40 Hz decrease in the resonance frequency of the
biotin derivatized crystal was observed, indicating the binding
occurrence and conﬁrming the binding capacity of the
SAMN@avidin complex.
Furthermore, data on avidin binding on SAMN surface were
analyzed according to the Langmuir isotherm model.32 The
analysis was carried out on the assumptions that each binding
site acts independently of other sites.33 The surface fractional
coverage of protein was calculated using the following
saturation function:34,35




1 [ ]max (2)
where θ is the surface fractional coverage of bound protein,
Γmax is the surface concentration of protein at the full
monolayer coverage, K is the apparent binding constant, and
Γ is the surface concentration of associated proteins when the
bulk concentration of protein is [P]. A linear plot of the
experimentally determined θ − 1 as a function of [P] − 1 yields
the value of the binding constant, K. In the case of the SAMN@
avidin complex, Γmax was 100 μg mg−1 and K was 45.18 μL
μg−1. The comparison with literature on nanoparticle surface
binding of proteins showed comparable results.36 A value of
Γmax 100 μg mg−1 corresponds to 17 avidin molecules in a close
packed geometry. Bound avidin was also determined by
measuring the disappearance of free avidin absorbance at 280
nm (ε280 nm = 6.99 × 104 M−1 cm−1), as a function of increasing
nanoparticle concentration, in the range 200−1800 mg L−1, in
50 mM tetramethylammonium perchlorate, pH 7.0. Exper-
imental data showed the presence of 12 ± 3 (n = 5) avidin
molecules per nanoparticle, in good agreement with the
maximum coverage capacity calculated according to the
Langmuir isotherm model. As a comparison, the possible
theoretical number of avidin molecules on SAMN surface,
considering the geometry of the protein on a sphere of 5.5 nm
radius, gives 11−16 avidin molecules per nanoparticle
(considering diﬀerent protein orientations).
The biological activity of SAMN@avidin complex was
evaluated and the number of available biotin binding sites
was determined, using biotinyl-ﬂuorescein as a probe, showing
that each bound avidin molecule is able to bind 2.8 ± 0.8 biotin
molecules, conﬁrming the maintenance of biological activity
and excellent binding capacity of SAMN@avidin.
Human SERCA, Isoform 2a, Puriﬁcation. Yeast culture
(4 L) was used for each puriﬁcation trial, from which about 115
g of dry cell pellet was recovered. The estimated total protein
content in the membrane fraction was of about 26 mg.
Since recombinant human SERCA-2a (hSERCA-2a-
(R863G)-BAD) competes with the endogenous biotinylated
proteins for the binding to avidin, a large excess (134 mg) of
SAMN@avidin was used for the puriﬁcation. Furthermore the
Coomassie stained gels showed that a signiﬁcant amount of the
recombinant protein was still present in the supernatant after
incubation with the nanoparticles (Figure 6). Therefore an
additional puriﬁcation step with SAMN@avidin was performed,
by incubating the supernatant previously recovered with fresh
nanoparticles, to increase the recovery of the recombinant
protein. Elution of the protein was achieved by overnight
incubation of the nanoparticles with thrombin. The fusion
hSERCA-2a(R863G) protein was then released in the super-
natant, while the BAD domain remained immobilized onto the
SAMN@avidin surface. About 1 mg of protein was obtained
from magnetic aﬃnity puriﬁcation with SAMN@avidin. The
puriﬁcation steps were followed by Coomassie stained PAGE-
electrophoresis and Western blot, from the crude yeasts lysate
to the gel ﬁltration puriﬁed product. As shown in Figure 6, a
major band of about 80 kDa was visible in Coomassie stained
gels. This band was also detected by Western blot analyses with
rabbit polyclonal anti-SERCA (Figure 7) and is therefore
attributable to hSERCA-2a(R863G). The diﬀerence between
Figure 4. TEM image of the SAMN@avidin complex.
Figure 5. FTIR spectrum of the SAMN@avidin complex. Nano-
particles samples were lyophilized, homogenized with KBr powder and
pelleted by an 8.0 tons hydraulic press. (―) SAMN, (---) avidin,
and (····) SAMN@avidin.
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the apparent molecular weight of puriﬁed SERCA-2a(R863G)
(80 kDa) and the expected weight, reported in the literature
(115 kDa), is attributable to the eﬀect of the detergent on the
electrophoretic mobility of the protein in SDS-PAGE, as often
reported for hydrophobic proteins in the presence of
detergents.36 Finally, a gel-ﬁltration step (Figure S3) performed
to increase protein purity and to eliminate excess thrombin
yielded to 500 μg of puriﬁed protein. The amount of
recombinant rabbit SERCA-1a was previously estimated to be
about 3% of the total protein content in the membrane fraction
of S. cerevisiae.15 Because of the high sequence similarity
between rabbit SERCA-1a and hSERCA-2a(R863G)-BAD, it is
possible to assume that the expression levels of the two proteins
in yeast are the same. Therefore, based on this assumption, we
calculated a yield in the puriﬁcation process of about 64%.
The stability of the SAMN@avidin complex was veriﬁed.
SAMN@avidin complex was stored in sterile 50 mM
tetramethylammonium perchlorate, pH 7.0, at 4 °C, and it
was successfully applied for hSERCA-2a(R863G) puriﬁcation
within 6 months.
SAMN@avidin Regeneration. After hSERCA-2a(R863G)
puriﬁcation, the biotin binding domain (BAD) remains bound
SAMN@avidin (SAMN@avidin-BAD). The regeneration of
SAMN@avidin was successfully accomplished by using a
modiﬁcation of the method proposed by Promega Corporation
for the Softlink Soft Release Avidin Resin. Brieﬂy, SAMN@
avidin-BAD was incubated in 10% acetic acid, containing an
excess of biotin (1 mM), under continuous stirring at 4 °C, in
order to partially denature immobilized avidin and to compete
with bound biotin binding domain (BAD) and other
biotinylated proteins, derived by the yeast colture. A large
amount of biotin had been used in order to guarantee the total
and irreversible protein removal. After SAMN@avidin washing
twice with 1 mM biotin in 10% acetic acid, biotin was removed
by washing SAMN@avidin twice with 10% acetic acid.
Immobilized avidin was refolded in 0.1 M potassium phosphate
buﬀer, pH 7.0. The biological activity of the regenerated
SAMN@avidin was tested by titration of biotin binding sites
with biotinylated ﬂuorescein, as described in Methods. After
regeneration, each avidin molecule bound to SAMN surface is
able to bind 2.0 ± 0.4 biotin molecules, indicating that after
hSERCA-2a puriﬁcation and regeneration, SAMN@avidin
maintain 60% of its puriﬁcation eﬃciency.
■ DISCUSSION
Surface characteristics of bare SAMNs confer the peculiar
ability to form colloidal suspensions, stable for months,
suggesting a network of interactions with water molecules
and repulsive forces, inhibiting nanoparticle aggregation. At the
same time, nanoparticle surface is able to interact with organic
molecules in solution. In our previous work we presented a
simple electrostatic model to explain SAMN peculiar surface
properties6 and in a following paper we used rhodamine
isothiocyanate, as a ﬂuorescent surface probe, suggesting a
multiple point binding, involving both electrostatic interactions
and complex formation with under-coordinated iron atoms on
SAMNs surface, generated by crystal truncation.38 In the
present report we found further evidence of the involvement of
under-coordinated iron atoms on SAMN surface in the binding
with biological molecules. A strong evidence of the presence of
under-coordinated iron atoms on SAMN surface was obtained
by Prussian Blue formation after incubation of SAMNs in
K4Fe(CN)6 containing solutions. The UV−vis spectrum of the
SAMN@Fe(CN)6
4‑ was similar to that presented by Zhao et
al.39 (Figure 1) on magnetite nanoparticles covered by Prussian
Blue. In our case no addiction of Fe3+ was necessary for the
Figure 6. Coomassie stained SDS-PAGE of the diﬀerent puriﬁcation
steps of hSERCA-2a(R863G) with SAMN@avidin. Collected samples
were diluted in SDS-PAGE loading buﬀer (20 μL of sample diluted in
20 μL loading buﬀer) and 20 μL of the resulting mixture were loaded
on a 10% polyacrylamide gel as follow. 1: membrane pellet; 2:
solubilized fraction; 3: supernatant after incubation with SAMN@
avidin; 4: washing fraction (with 1 M KCl); 5: eluted fraction from the
magnetic puriﬁcation with SAMN@avidin; 6: eluted fraction from
SEC-FPLC (size-exclusion chromatography-fast protein liquid chro-
matography); 7: molecular weight markers.
Figure 7. Western blotting analyses of puriﬁed fractions. Samples of
the eluted fractions were diluted in loading buﬀer (as previously
described) and loaded on an SDS-PAGE acrylamide gel. After
electrophoresis, the proteins were transferred to nitrocellulose
membranes and hSERCA-2a was detected with rabbit polyclonal
antibodies against SERCA (SERCA1/2/3, Santa Cruz Biothecnology)
as primary antibody, and with mouse antirabbit conjugated with horse
radish peroxidase (AMS Biotechnology ltd). 1: membrane pellet; 2:
solubilized fraction; 3: supernatant after incubation with SAMN@
avidin; 4: washing fraction (with 1 M KCl); 5: eluted fraction from the
magnetic puriﬁcation with SAMN@avidin; 6: eluted fraction from
SEC-FPLC (size-exclusion chromatography-fast protein liquid chro-
matography); 7: molecular weight markers.
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reaction taking place, conﬁrming both the presence of under-
coordinated Fe3+ on SAMN surface and their availability toward
chelating molecules. Up to author knowledge few reports can
be found in literature about optical characteristics of water
suspensions of bare nanocrystalline maghemite,40 probably
because it is unusual to obtain stable colloidal suspensions of
this kind of material. According to Sherman et al.41 iron oxide
optical properties, peculiar of semiconductor metal oxides, can
be explained considering that the valence band consists mostly
of O(2p)-like orbitals, together with the occupied Fe(3d)
orbitals, and the conduction band consists of unoccupied
Fe(3d) orbitals. Thus, the band gap corresponds to a ligand-to-
metal charge-transfer (LMCT) transition, O(2p) → Fe(3d).
Although the band gap of maghemite is 2.01 eV (611 nm), the
visible transitions are thought to be indirect transitions (d → d
type).38 Depending on the iron oxide material, direct
transitions from O(2p) valence band orbitals to the conduction
band edge occur in the range comprised between 3 and 4.7 eV
(257−413 nm).42 As consequence, in agreement with literature
prediction, our 400 nm maximum absorption wavelength is
attributable to the direct transitions from O(2p) valence band
orbitals to the conduction band edge. Furthermore, optical
properties of metal oxide in the nanometer range size are
expected to be sensitive to surface characteristics.43 Conversely,
the modiﬁcation of nanoparticle surface will reﬂect on optical
spectrum, as we observed on SAMNs upon salt addition, pH
variations and biomolecule binding (see Figures 1, 2, and S2).
Rajh et al43 found a comparable binding behavior of TiO2,
ZrO2, and Fe2O3 toward chelating ligands. The phenomenon is
exclusively characteristic of metal oxide systems displaying
colloidal stability, high crystallinity, dimensions below 20 nm,
and SAMNs perfectly adhere to these requirements. In this size
domain the surface atoms adjust their coordination environ-
ment to form under-coordinated metal sites and ligand binding
is favored because of the stability gained from ligand adsorption
induces a restructuration of the nanoparticle surface. As a
consequence, surface modiﬁcation of nanocrystalline metal
oxide particles alters nanoparticle optical properties.43 Avidin
and biotin probably adjust the coordination geometry of the
surface Fe3+ atoms and shift the onset of absorption band
toward the visible region of the spectrum, compared to
unmodiﬁed SAMNs. The solvent, as well, inﬂuences SAMN
optical absorption, by interacting with the under-coordinated
sites on SAMNs surface.
The possibility to form stable interactions with selected
organic molecules leads us to propose the avidin−biotin couple
for SAMN derivatization. In particular, SAMN@biotin resulted
unuseful for biotechnological application, even if informative
about nanoparticle surface properties, possibly conﬁrming the
presence of under-coordinated iron(III) atoms on nanoparticle
surface, as already suggested.23 The higher complexity of FTIR
spectrum of avidin did not allow us to distinguish about the
involvement of speciﬁc protein functional groups in SAMN
binding. Nevertheless, avidin binds on nanoparticle surface by a
monomolecular layer eﬀectively and quickly, by simple
incubation in aqueous solution without any expensive reagent
or cumbersome procedure, thus reducing the overall
unoccupied surface area and, as a consequence, reducing
nonspeciﬁc protein absorption phenomena and achieving a
high speciﬁcity.
Protein structural changes upon binding on a solid surface
are well documented.31 These protein conformational mod-
iﬁcation may negatively aﬀect ligand accessibility and, in the
case of avidin, the biotin binding site recognition properties and
availability. For this reason, the biological activity of SAMN@
avidin complex was studied, in terms of number of biotinylable
sites, by using a ﬂuorescent probe, namely biotinyl-ﬂuorescein.
From the experimental data, each avidin molecule immobilized
on SAMN surface is able to bind 2.8 ± 0.8 biotin molecules,
indicating a good binding capacity of SAMN@avidin, and, as
consequence, the absence of signiﬁcant changes in protein
structure and of its binding sites.
Furthermore, SAMN@avidin complex was successfully
applied to the puriﬁcation of a membrane protein, namely
recombinant human SERCA-2a(R863G), previously biotiny-
lated in S. cerevisiae, which present a still unknown structure.
The proposed system enabled the magnetic aﬃnity isolation of
human SERCA-2a(R863G), from yeast lysate, with an
estimated 64% yield and SAMN@avidin, after the puriﬁcation
procedure, was regenerated by an optimized method.
The high speciﬁcity exhibited by SAMN on protein
separation suggests that these magnetic nanoparticles could
be successfully used as a general and versatile system for protein
isolation, possibly feasible for other biological targets.
■ CONCLUSIONS
A new category of maghemite nanoparticles (SAMNs), with a
size of about 10 nm, has been proposed and applied. Despite
XRD, low-temperature, and in-ﬁeld Mössbauer and FTIR
spectroscopic data, conﬁrm that SAMNs are composed of
stochiometric maghemite,5,6 these particles, easily matching
with the interest in biotechnology, revealed diﬀerent surface
characteristics from other reported maghemite nanoparticles.
Beyond the peculiar dispersion properties, giving stable water
colloidal suspensions without any organic or inorganic
coverage, and the possibility to adsorb organic molecules, we
ﬁrst evidenced a unique titration behavior and peculiar UV−vis
spectrum. We pointed out the accessibility and availability of
under-coordinated Fe3+ by a simple reaction with K4Fe(CN)6
leading to Prussian Blue formation, and we illustrated that
SAMN spectral parameters appear to depend on the buﬀer, on
suspension pH and on coupling biomolecules, indicating that
nanoparticle optical characteristics are governed by surface
properties, in agreement with surface reconstruction theory,43
probably justifying the peculiar behavior of SAMN suspensions,
their high stability in water and their ability of adsorbing
biomolecules, features that lead us to propose a new
biotechnological device, such as SAMNs@avidin, which can
be successfully used to isolate and purify biotinylated proteins.
Despite signiﬁcant and considerable recent improvements,
the expression and the subsequent puriﬁcation of functionally
folded membrane proteins in suﬃcient amounts for functional
and structural studies is still a challenging task; we used the
proposed system to purify a hydrophobic membrane protein,
the recombinant hSERCA-2a, expressed for the ﬁrst time in
yeast. Few expression systems are successfully used to produce
milligram quantities of membrane proteins, in recent years,
yeasts have become the second most popular membrane
proteins expression system, after E. coli, more cost-eﬀective
than expression in mammalian or insect cell lines and often
showing higher yields. Structural studies require that puriﬁed
membrane proteins should be chemically and conformationally
homogeneous, stable at relatively high concentrations and
available in milligram amounts, as consequence, high expression
rates are necessary. In this report we were able to purify for the
ﬁrst time recombinant hSERCA-2a, expressed in yeast, in the
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presence of a great amount of fouling agents, other competitive
biotinylated proteins and detergents. Our system allowed us to
reach the promising yield of 500 μg, a suﬃcient amount for the
characterization of membrane proteins by in vitro approaches.
Moreover, the complete puriﬁcation process, from SAMNs




Size distribution of SAMNs (Figure S1), optical spectra of
SAMN@avidin and SAMN@biotin suspension (Figure S2),
and chromatographic exclusion proﬁle from SEC-FPLC of
hSERCA-2a(R863G) (Figure S3). This material is available free
of charge via the Internet at http://pubs.acs.org.
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